Report Sections

See All Reports

  • HP:0000716: Depressivity
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000716: Depressivity

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (73)


    Name (Synonyms) Correlation
    drug2273 MagPro X100 Stimulator, B70 Fluid-Cooled Coil Wiki 0.26
    drug59 38 questions questionnaire Wiki 0.19
    drug4548 lay telephone coaching Wiki 0.19
    Name (Synonyms) Correlation
    drug2136 Lifestyle change promotion program Wiki 0.19
    drug4632 online mindfulness group Wiki 0.19
    drug648 Brief Behavioral Activation Treatment Wiki 0.19
    drug700 CHAMindWell Wiki 0.19
    drug4581 mindfulness, emotion didactics, interpersonal skills, experiential learning Wiki 0.19
    drug4684 quesionnair Wiki 0.19
    drug1313 EMDR Wiki 0.19
    drug4734 sham TMS Wiki 0.19
    drug4314 Written Information Wiki 0.19
    drug4815 zinc gluconate and ascorbic acid Wiki 0.19
    drug4612 non applicable Wiki 0.19
    drug4764 suspected of COVID-19 infection Wiki 0.19
    drug550 Best available treatment Wiki 0.19
    drug1665 Growth Mindset SSI Wiki 0.19
    drug1317 EPDS (Edinburgh Postnatal Depression Scale) Wiki 0.19
    drug2811 Pandemic control measures Wiki 0.19
    drug4806 vitamin d Wiki 0.19
    drug3814 Supportive Therapy SSI Wiki 0.19
    drug583 Biospecimen collection Wiki 0.19
    drug4543 iv Tocillizumab (TCZ) Wiki 0.19
    drug4721 self-care tools Wiki 0.19
    drug570 Biological/Vaccine: Angiotensin peptide (1-7) derived plasma Wiki 0.19
    drug3122 Prospective study across two time-points examining the impact of viral mitigation protocols on mental health Wiki 0.19
    drug1977 Internet Cognitive Behavioral Therapy plus CHAMindWell Wiki 0.19
    drug3889 TMS Wiki 0.19
    drug1524 Feeling Good Digital App Wiki 0.19
    drug4769 teleconsultation Wiki 0.19
    drug528 Behavioral Activation SSI Wiki 0.19
    drug4763 surveys and questionnaires Wiki 0.19
    drug4546 lanadelumab Wiki 0.19
    drug529 Behavioral Activation in real-life Wiki 0.19
    drug4706 rhDNase I Wiki 0.19
    drug2140 Limbix Spark Wiki 0.19
    drug3907 Taste test Wiki 0.19
    drug702 CHLORPROMAZINE (CPZ) Wiki 0.19
    drug2381 Mindfullness based cognitive program Wiki 0.19
    drug2391 Mindfulness exercises Wiki 0.19
    drug2776 PHQ-9 (Patient Health Questionnaire) Depression Scale Wiki 0.19
    drug2693 Online Intervention Mental Health COVID-19 Wiki 0.19
    drug3533 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] Wiki 0.19
    drug2385 Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell Wiki 0.19
    drug4731 service of questionnaire Wiki 0.19
    drug3070 Prednisone tablet Wiki 0.19
    drug580 Biosensor Wiki 0.19
    drug4239 Virtual Reality Behavioral Activation Wiki 0.19
    drug1588 GAD-7 (General Anxiety Disorder) scale Wiki 0.19
    drug604 Blood plasma Wiki 0.19
    drug4542 it is a survey Wiki 0.19
    drug539 Bereavement Virtual Support Group Wiki 0.19
    drug367 Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery Wiki 0.19
    drug460 BGB-DXP593 Wiki 0.19
    drug4553 liposomal lactoferrin Wiki 0.19
    drug3554 Self-System Therapy Wiki 0.19
    drug3534 Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] Wiki 0.19
    drug4700 regular care Wiki 0.19
    drug4151 Universal Screening Arm Wiki 0.19
    drug4638 other Wiki 0.13
    drug3135 Psychoeducation Wiki 0.13
    drug754 COVID-19 RT-PCR Wiki 0.11
    drug4749 standard of care Wiki 0.11
    drug4719 self-administered questionnaire Wiki 0.11
    drug2706 Online survey Wiki 0.09
    drug3730 Standard of Care (SOC) Wiki 0.08
    drug4761 survey Wiki 0.07
    drug4687 questionnaire Wiki 0.07
    drug832 Camostat Mesilate Wiki 0.07
    drug963 Colchicine Wiki 0.05
    drug3829 Survey Wiki 0.05
    drug3192 Questionnaire Wiki 0.03
    drug2916 Placebo Wiki 0.02

    Correlated MeSH Terms (18)


    Name (Synonyms) Correlation
    D003866 Depressive Disorder NIH 1.00
    D003863 Depression, NIH 0.53
    D003865 Depressive Disorder, Major NIH 0.42
    Name (Synonyms) Correlation
    D019052 Depression, Postpartum NIH 0.25
    D001008 Anxiety Disorders NIH 0.19
    D001238 Asphyxia Neonatorum NIH 0.19
    D000067292 Alcohol Drinking in College NIH 0.19
    D061218 Depressive Disorder, Treatment-Resistant NIH 0.19
    D001714 Bipolar Disorder NIH 0.13
    D020920 Dyssomnias NIH 0.08
    D020447 Parasomnias NIH 0.07
    D013315 Stress, Psychological NIH 0.07
    D040921 Stress Disorders, Traumatic NIH 0.07
    D013313 Stress Disorders, Post-Traumatic NIH 0.06
    D002055 Burnout, Professional NIH 0.06
    D020521 Stroke NIH 0.05
    D000077062 Burnout, Psychological NIH 0.04
    D004194 Disease NIH 0.03

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0012768 Neonatal asphyxia HPO 0.19
    HP:0100754 Mania HPO 0.13
    HP:0001297 Stroke HPO 0.05

    Clinical Trials

    Navigate: Correlations   HPO

    There are 29 clinical trials


    1 Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

    Background: Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI) scans helps locate the best area for rTMS in each person. They also want to find other ways to make it more effective. Objective: To study the effects of combining MRI- guided transcranial magnetic stimulation (TMS) and talk therapy on the brain in people with depression. Eligibility: Adults ages 18-65 with a major depressive disorder and current depression. If taking an antidepressant, should have been doing so for at least 4 weeks. Design: Participants will be screened with medical and psychiatric history, psychiatric evaluation, physical exam, and blood and urine tests. Phase 1 is 1-4 visits in 1 week. Participants will have: - Brain MRI. Participants will lie on a table in a scanner. - Questions about their medical history and psychology symptoms - Tests of mood and thinking - Tests of brain activity. Participants may do tasks during these tests: - A cone with magnetic detectors is put on the head. - A cap with electrodes is put on the scalp. - TMS. A brief electrical current passes through a wire coil on the scalp. - A metal disk will be placed on the arm. A nerve will be stimulated with a small electrical shock. Phase 2 is about 6 to 7 weeks. - There will be 30 daily sessions of combined therapy and repetitive TMS (rTMS) for 6 weeks. - Participants will receive rTMS and another therapy by computer. - For rTMS, repeated pulses will pass through the coil. - This is followed by up to 3 additional visits, when: - Participants will repeat Phase 1 tests - Participants will rate their depression symptoms. Phase 3 is 3 visits over 3 months. Participants will rate their depression symptoms and repeat some of the previous questionnaires and tests of mood and thinking.

    NCT03289923
    Conditions
    1. Major Depressive Disorder
    Interventions
    1. Other: sham TMS
    2. Device: TMS
    3. Behavioral: Self-System Therapy
    4. Behavioral: Mindfulness exercises
    MeSH:Depressive Disorder Depression Depressive Disorder, Major
    HPO:Depressivity

    Primary Outcomes

    Description: change in magnitude of BOLD signal with fMRI bold signal from DLPFC

    Measure: Change in magnitude of Bold signal

    Time: 6 weeks after initiating intervention

    Secondary Outcomes

    Description: Recordings of brain activity

    Measure: Electrophysiological changes using MEG and EEG measures

    Time: 6 weeks after initiating intervention

    Description: Clinical symptom scales from which we derive scores

    Measure: Clinical Rating Scales: BSL, C-SSRS, CTQ, HAM-A, NIH-BFI, PANAS, RBANS, RRS, SHAPS, and TLEQ

    Time: Variable: some 6 weeks after initiating intervention; others weekly
    2 Characterization and Treatment of Adolescent Depression

    Background: Almost 20% of Americans have depression. It is a leading cause of disability because it is chronic and it starts early. The highest incidence is among adolescents and young adults. But researchers don t know much about why some people become depressed whilst others don t. One possibility is that the way people process rewarding stimuli could be related to their risk for depression. Objective: To characterize and treat depression in youth by focusing on reward processing. Eligibility: People ages 11 17 with major depressive disorder or subthreshold depression Healthy volunteers ages 11 17 Design: Participants will be screened with interviews and questionnaires. They will have memory, thinking, and concentration tests. They may have a urine pregnancy test or have photos or videos taken. At the initial visit, participants will: Perform tasks and be interviewed Have functional magnetic resonance imaging (MRI) scans. For this, participants will lie in a metal cylinder in a magnetic field. They will do study tasks while looking at a screen in the scanner. Look at pictures of stimuli that signal win (rewards) or loss and get money for making certain choices. Have brain and eye activity monitored Do tasks in a virtual reality environment Wear an activity monitor Choose to have blood taken for research studies Perform tasks while in magneto-encephalography a machine that uses sensitive magnetic sensors to measure the brain s electric activity Participants will get phone prompts at home to ask about their mood. Participants will have several follow-up visits the first year, then 1-2 each year until they are 25. They will repeat some tasks above. Some participants with depression can elect to receive outpatient treatment at NIH and can receive inpatient treatment at NIH, if they wish. None of the treatments are experimental, that is, all treatments are standard and have an evidence base. Patients will have more visits before and after they have treatment. They will do some of the tests above plus drug testing. Participants who are in treatment and their parents will talk with a Senior Attending physician, a nurse, social worker, or psychologist. Those in outpatient treatment will have practice work between visits. Those who are inpatients will have practice work during their inpatient treatment and adjustments to medication can be made.

    NCT03388606
    Conditions
    1. Depression
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: changes in MFQ scores over time

    Measure: Mood and Feelings Questionnaire

    Time: Ongoing
    3 Using a Diagnostic Taste Test as a Surrogate Biomarker to Predict Drug Effectiveness in Patients With Depression (MDD)

    The study will be looking at whether a taste test device can be used as a diagnostic aid for depression. Taste tests will be carried out before and after first use of an antidepressant (prescribed by the patient's GP) and then again a month later a further taste test will be conducted. The results of these tests will be assessed to see if they correlate with the outcome of validated mood questionnaires carried out at the first and second visits.

    NCT03645447
    Conditions
    1. Depression
    Interventions
    1. Diagnostic Test: Taste test
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: Change in taste threshold measures (sweet, salt, bitter, sour) between baseline and post-probe(s) at day 1 and 28 days after antidepressant treatment is initiated is assessed with the assistance of a taste test device.

    Measure: Change in taste threshold with antidepressant treatment

    Time: 4-6 weeks (per patient)

    Description: Change in mood (assessed by score on the Beck Depression Inventory (BDI)) with antidepressant treatment is assessed. BDI scores may range from 0-63, where 0 demonstrates the lowest depression score and 63 the most severe depression.

    Measure: Change in mood (assessed by score on the Beck Depression Inventory) with antidepressant treatment

    Time: 4-6 weeks (per patient)

    Secondary Outcomes

    Description: Changes in scores on the Clinical Global Impression scale, as assessed by the participant's general medical practitioner is recorded. This scale ranges from 0-7, where 0 is the least severely ill and 7 the most severely ill.

    Measure: Change in mood with antidepressant treatment, measured by the Clinical Global Impression Scale (CGI scale)

    Time: 4-6 weeks (per patient)

    Description: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9). PHQ9 scores range from 0-27, where 0 is the score for the least depressed patients and 27 the most severely depressed patients.

    Measure: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9)

    Time: 4-6 weeks (per patient)

    Description: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS). HADS scores for depression range from 0-21, where 0-7 is normal, 8-10 borderline and 11+ indicates clinical depression

    Measure: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS)

    Time: 4-6 weeks (per patient)

    Description: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS). Scores for QIDS range from 0-27, where 0 indicates no symptoms of depression and 27 indicates the most severe depression.

    Measure: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS)

    Time: 4-6 weeks (per patient)

    Description: A computerised algorithm will be used to direct the taste test to assess taste sensitivity. The algorithm has been developed to direct the taste test, indicating which taste solutions should be presented to the participant in which order. Every solution presented is recorded, along with answers given. These will be examined after testing to validate the code's ability to follow the algorithm created and properly determine taste thresholds.

    Measure: Validation of diagnostic algorithm, comparing the sequence of taste testing determined by software with the algorithm described in the software specification.

    Time: 12 months (duration of trial)

    Description: User views on ease of use of the device and testing process will be collected. Users will be asked to give ease of use a score from 1-5, where 1 is very easy and 5 is very difficult. Participants will also be asked whether they would use the taste test again.

    Measure: User assessment of ease of use of the device and testing process.

    Time: 4-6 weeks (per patient)
    4 Randomized Controlled Trial of Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

    The primary goal of the proposed study is to compare the effectiveness of universal school based screening for adolescent major depressive disorder to the current school process of targeted screening based on concerning behavior.

    NCT03716869
    Conditions
    1. Major Depressive Disorder
    2. Major Depressive Episode
    Interventions
    1. Other: Universal Screening Arm
    MeSH:Depressive Disorder Depression Depressive Disorder, Major
    HPO:Depressivity

    Primary Outcomes

    Description: Universal 1) Adolescents with PHQ-9 score >10 (screen Sept-Mar of the school year) or who at any point in the year exhibit behavior concerning for MDD prompting a SAP triage request, 2) Adolescents identified with MDD by SAP triage, and 3) Adolescents who successfully engage with at least one SAP recommendation. Prior Sept-Nov screening adjusted per school preference. Targeted 1) Adolescents with behavior concerning for MDD prompting a SAP triage request, 2) Adolescents identified with MDD by SAP triage, and 3) Adolescents who successfully engage with at least one SAP recommendation Concern for MDD based on a primary or secondary potentially MDD related SAP "incoming referral reason" SAP triage is not diagnostic, so MDD identified based on recommendations for MDD related school or community services (e.g. mental health treatment services) HRSA funds mostly rural schools (anticipated N=4738; all rural but one school) and PCORI funds urban schools (anticipated N=7768)

    Measure: MDD composite: Adolescents MDD screen positive by PHQ-9 (universal arm) or with concern for MDD prompting Student Assistance Program (SAP) triage request, identified with MDD by SAP, and who engage with at least one SAP recommended service or treatment

    Time: up to 9 months

    Secondary Outcomes

    Description: Universal screening arm: Adolescents who have a PHQ-9 score >10 (screening with the PHQ-9 is planned during the academic year, e.g. September to March) or who at any point in the school year exhibit behavior concerning for MDD which prompts self or collateral request for SAP triage. Targeted screening arm: Adolescents with behavior concerning for MDD which prompts self or collateral request for SAP triage at any point during the school year. Concern for MDD is based on a primary or secondary potentially MDD related SAP "incoming referral reason".

    Measure: MDD screen positive/concern: Adolescents who screen positive for MDD either by PHQ-9 (universal screening arm only) or by concern for MDD prompting a request for SAP triage

    Time: up to 9 months

    Description: Universal screening arm: Patient health questionnaire positive response to question #9 re: suicidal thoughts, which requires management by the state-mandated school crisis plan or student self or collateral report of suicidal thoughts, which requires management by the state-mandated school crisis plan (source school district). Targeted screening arm: Student self or collateral report of suicidal thoughts, which requires management by the state-mandated school crisis plan (source school district). Any student suicide attempts or completed suicides shared with the school district will also be included.

    Measure: Suicidal Adolescent

    Time: up to 9 months

    Description: Universal and targeted screening arms: Adolescents who are identified as having MDD based on triage by the school SAP team. As SAP triage is not diagnostic, MDD identified will be based on SAP recommendations for school or community services which are MDD related (e.g. mental health treatment services).

    Measure: MDD identification: Adolescents who are identified as having MDD based on triage by the school SAP team

    Time: up to 9 months

    Description: Universal and targeted screening arms: Adolescents who successfully engage with at least one SAP recommendation. This may be fulfilled by parental report that an appointment was successfully scheduled.

    Measure: MDD treatment engagement: Successful engagement with at least one SAP recommendation

    Time: up to 9 months

    Description: This performance measure represents the percentage of all students scoring Proficient or Advanced on the Mathematics Algebra I Keystone Exam. Algebra I Keystone scores reflect students' best score to date for all 11th grade students enrolled in the school for the full academic year.

    Measure: Standardized test scores: Keystone exams mathematics (school district). This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.

    Time: up to 9 months

    Description: This performance measure represents the percentage of all students scoring Proficient or Advanced on the ELA/Literature Keystone Exam. Literature Keystone scores reflect students' best score to date for all 11th grade students enrolled in the school for the full academic year.

    Measure: Standardized test scores: Keystone exams English language arts (ELA; school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.

    Time: up to 9 months

    Description: This performance measure represents the percentage of all students scoring Proficient or Advanced on the Science/Biology Keystone Exam. Biology Keystone scores reflect students' best score to date for all 11th grade students enrolled in the school for the full academic year.

    Measure: Standardized test scores: Keystone exams science (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.

    Time: up to 9 months

    Description: This performance measure represents the percent of 12th grade students who have taken the PSAT or Plan at any time over the course of their educational experience.

    Measure: Preliminary Scholastic Aptitude Test (PSAT)/Plan (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.

    Time: up to 9 months

    Description: This performance measure represents the percent of 12th grade students meeting both SAT College and Career Readiness benchmarks and/or scoring 22 or higher on the ACT taken at any time over the course of their educational experience.

    Measure: Scholastic Aptitude Test (SAT)/ American College Testing (ACT) performance (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.

    Time: up to 9 months

    Description: data aggregate by grade level only schools currently track the number of student policy violations (e.g. for drug and alcohol, violence) and student suspensions

    Measure: Student school policy violations and suspensions based on school district data

    Time: up to 9 months

    Description: data aggregate by grade level only

    Measure: Missed school days

    Time: up to 9 months

    Description: data aggregate by grade level only

    Measure: Grade point average

    Time: up to 9 months

    Description: data aggregate by grade level only

    Measure: Grade advancement: This measure represents the percent of students promoted in each grade for the school (grades 9-11, school district data)

    Time: up to 9 months

    Description: data aggregate by grade level only

    Measure: Graduation: This measure represents the percent of students who graduate 12th grade with a high school diploma (school district data)

    Time: up to 9 months

    Other Outcomes

    Description: Sex (Male, Female), Ethnicity, Race, Rural/Urban

    Measure: Subgroup analyses based on school district demographic data

    Time: up to 9 months
    5 Scaling Up Maternal Mental Health Care by Increasing Access to Treatment (SUMMIT): A Study Protocol for Perinatal Depression and Anxiety

    SUMMIT (Scaling Up Maternal Mental health care by Increasing access to Treatment) overarching goal is to examine the scalability and patient-centered provision of brief, evidence-based psychological treatments for perinatal depression and anxiety (N=1368). Specifically, and through a multi-site, randomized, pragmatic trial, the trial examines whether one brief, behavioral activation (BA) delivered via telemedicine is as effective as the same treatment delivered in person; and whether BA delivered by non-mental health nurses, with appropriate training is as effective as when delivered by specialist providers (psychiatrists, psychologists and social workers) in reducing perinatal depressive and anxiety symptoms. The study will be conducted in Toronto, Chicago and North Carolina. The trial will also identify relevant underlying implementation processes and determine whether, and to what extent, these strategies work differentially for certain women over others.

    NCT04153864
    Conditions
    1. Perinatal Depression
    Interventions
    1. Behavioral: Brief Behavioral Activation Treatment
    MeSH:Asphyxia Neonatorum Depression Depressive Disorder
    HPO:Depressivity Neonatal asphyxia

    Primary Outcomes

    Description: Brief BA psychological treatment is delivered by non-specialist providers. The perinatal depressive symptoms are measured by the Edinburgh Postnatal Depression Scale. The minimum and maximum values for the Edinburgh Postnatal Depression Scale are 0 and 30 respectively. Higher scale scores are associated with higher perinatal depressive symptoms. The assessment period is extended to account for post-treatment outcomes when there are interruptions to treatment (e.g., giving birth, obstetrical complications and COVID-19 related events).

    Measure: Treatment of perinatal depressive symptoms by non-specialist providers

    Time: 3-months post-randomization

    Description: Brief BA psychological treatment is delivered through telemedicine. The perinatal depressive symptoms are measured by the Edinburgh Postnatal Depression Scale. The minimum and maximum values for the Edinburgh Postnatal Depression Scale are 0 and 30 respectively. Higher scale scores are associated with higher perinatal depressive symptoms. The assessment period is extended to account for post-treatment outcomes when there are interruptions to treatment (e.g., giving birth, obstetrical complications and COVID-19 related events).

    Measure: Treatment of perinatal depressive symptoms through telemedicine

    Time: 3-months post-randomization

    Secondary Outcomes

    Description: Brief BA psychological treatment is delivered by non-specialist providers. The anxiety symptoms are measured by the Generalized Anxiety 7 Item Questionnaire. The minimum and maximum values for the Generalized Anxiety 7 Item Questionnaire are 0 and 21 respectively. Higher scale scores are associated with higher perinatal anxiety symptoms. The assessment period is extended to account for post-treatment outcomes when there are interruptions to treatment (e.g., giving birth, obstetrical complications and COVID-19 related events).

    Measure: Treatment of perinatal anxiety symptoms by non-specialist providers

    Time: 3-months post-randomization

    Description: Brief BA psychological treatment is delivered through telemedicine. The anxiety symptoms are measured by the Generalized Anxiety 7 Item Questionnaire. The minimum and maximum values for the Generalized Anxiety 7 Item Questionnaire are 0 and 21 respectively. Higher scale scores are associated with higher perinatal anxiety symptoms. The assessment period is extended to account for post-treatment outcomes when there are interruptions to treatment (e.g., giving birth, obstetrical complications and COVID-19 related events).

    Measure: Treatment of perinatal anxiety symptoms through telemedicine

    Time: 3-months post-randomization

    Description: Child mental development is measured by Bayley Mental Developmental Scale III and the provision of psychosocial stimulation by the mother measured by Home Observation Measurement Evaluation. Cognitive development, expressive and receptive language, and fine and gross motor development composite scores are measured by Bayley Mental Developmental Scale III. The composite scores are scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160. Higher scaled scores are associated with higher mental health development in child. The minimum and maximum values for the Home Observation Measurement Evaluation scale scores are 0 and 45 respectively. Higher scores are associated with more enriched environment.

    Measure: Child Mental Health Development

    Time: 9 to 15 months post child birth

    Description: Response and Remission is measured by Patient Health Questionnaire 9. The minimum and maximum values for Patient Health Questionnaire 9 are 0 and 27 respectively. Response and Remission is defined as PHQ-9 of less than 10 and 5 respectively. The assessment period is extended to account for post-treatment outcomes when there are interruptions to treatment (e.g., giving birth, obstetrical complications and COVID-19 related events).

    Measure: Response and Remission

    Time: 3-months post-randomization
    6 Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder

    The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD). The secondary purpose of this study is to examine whether any evidence of clinical efficacy exists for VR delivered BA.

    NCT04268316
    Conditions
    1. Major Depressive Disorder
    2. MDD
    3. Depression
    Interventions
    1. Device: Virtual Reality Behavioral Activation
    2. Behavioral: Behavioral Activation in real-life
    MeSH:Depression Depressive Disorder Depressive Disorder, Major
    HPO:Depressivity

    Primary Outcomes

    Description: This outcome will be measured using the "Intention to use Technology " questions of the Technology Acceptance Model questionnaire. These are questions 11, 12, and 13 and allow participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.

    Measure: Participant's desire to continue using VR after the study ends

    Time: 4-weeks

    Description: Participant treatment dropout will be compared across each study arm.

    Measure: Rates of dropout of VR-BA

    Time: 4-weeks

    Description: This outcome will be measured using the "Attitudes Toward Use " questions of the Technology Acceptance Model questionnaire. These are questions 7, 8, 9, and 10 and allow participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.

    Measure: Participant's satisfaction with the VR-BA treatment

    Time: 4-weeks

    Description: This will be measured by noting the amount of times the VR headset is used.

    Measure: Participant's use of the VR headset

    Time: 4-weeks

    Description: This will be measured using the overall Technology Acceptance Model questionnaire, which encompasses 13 questions and allows participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.

    Measure: Participant's acceptance of VR-BA treatment

    Time: 4-weeks

    Description: This will be determined by the Simulator Sickness Questionnaire, which names 16 adverse symptoms and asks participants to circle as compared to baseline: No more than usual, Slightly more than usual, Moderately more than usual, or Severely more than usual.

    Measure: How well can participants tolerate the VR-BA treatment?

    Time: 4-weeks

    Description: This will be measured using the Presence Questionnaire, which asks three questions and asks the participants to circle either Not at all, Slightly, Moderately, Strongly, or Very Strongly.

    Measure: How present did individuals in the VR-BA treatment feel?

    Time: 4-weeks.

    Secondary Outcomes

    Description: How participants' depression scores PHQ-9 change over time using VR-BA compared to BA in real life and a waitlist control. The PHQ-9 is a 9-question screener with a score range of 0-29, with 29 indicating the most severe depression and 0 indicating a lack of depression symptoms.

    Measure: Clinical efficacy of using VR as a tool to deliver BA

    Time: 4-weeks
    7 Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression

    Postnatal depression is an important problematic in French population with approximatively 10 -20% of women who suffer from postnatal depression. This pathology may have strong negative impact on both women and neonate's health. The women's satisfaction degree in front of childbirth is an important factor associated with postnatal depression since women unsatisfied of their childbirth and/or women with a complicated childbirth are more encline to suffer from postnatal depression. It is likely that the actual context of Covid 19 pandemia and the change in obstetrical cares organization may have a negative impact on women's satisfaction about their childbirth and so a negative impact on the risk of postnatal depression.

    NCT04368208
    Conditions
    1. Postnatal Depression
    Interventions
    1. Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery
    MeSH:Depression, Postpartum Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: proportion of women with an Edinburgh score higher than 12 between 4 and 6 weeks postpartum

    Measure: Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia

    Time: 4-6 weeks postpartum

    Secondary Outcomes

    Description: Existence of an association with postnatal depression and these factors: socio demographic women's characteristics, modalities of pregnancy management, satisfaction and experience about delivery, postnatal pelvic floor disorders, self rated health for the woman and the child, modalities of delivery, prenatal anxiety

    Measure: Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia

    Time: 4-6 weeks postpartum

    Description: Scale from 0 to 10 of satisfaction ; answers to the WOMBLSQ4 questionnaire about childbirth experience and satisfaction

    Measure: Describe the experience and the satisfaction about delivery during the covid 19 pandemia

    Time: within the week after delivery
    8 Parenting in a Pandemic: Parental Stress During the COVID-19 and Its Association With Depression and Anxiety

    This study seeks to investigate the levels of parental stress across different demographic subgroups in the general parental population during the strict social distancing government-initiated non-pharmacological interventions (NPI's) related to the COVID-19 pandemic. The study also seeks to examine the predictors of parental stress rates related to these non-pharmacological interventions (NPI's). In addition, the research will investigate the association between parental stress associated and psychopathology symptoms (i.e., depression and generalized anxiety). The aim of the project is to: - Inform the policymakers, the general public, scientists, and health practitioners about the psychological associations of the COVID-19-related government-initiated measures on parental stress, with special focus on the school and kindergarten lockdowns. - Provide a foundation for policymakers and health-care professionals to employ interventions that protect families against possibly increased psychological stressors. - Help policymakers and healthcare professionals to better understand the association of demographic variables and other predictors on parental stress and parent-child dysfunction, which information necessary for evaluating the psychological impact of NPIs on parental stress and thus the framework under which decisions about school/kindergarten lockdowns are made.

    NCT04377074
    Conditions
    1. Parental Stress
    2. Depression
    3. Anxiety
    MeSH:Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity

    Primary Outcomes

    Description: Three items from the Danish Parental Stress Scale (PSS) was selected, which intends to be a short measure of perceived stress resulting from being a parent (Pontoppidan et al., 2018). The scale consists of nine items measuring parental stress where each is measured on a five-point Likert scale (1-5), with the scores ranging from 3 to 15. Higher scores indicate higher parental stress. The following three were chosen in this large-scale investigation: 1) I feel overwhelmed by the responsibility of being a parent. 2) The major source of stress in my life is my child(ren), and 3) It is difficult to balance different responsibilities because of my child(ren) (Pontoppidan et al., 2018).

    Measure: Measure of parental stress

    Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway

    Description: The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.

    Measure: Patient Health Questionnaire 9

    Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway

    Description: The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Higher scores indicate greater anxiety severity, and scores that are above the cutoff of 10 are considered to be in the clinical range (Spitzer et al., 2006). Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).

    Measure: Generalized Anxiety Disorder 7

    Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway
    9 Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic - a Web-based Cross-sectional Survey

    The article presents a protocol of a cross-sectional study of mental health of pregnant women in relation to the COVID 19 pandemic. The primary aim is to compare differences in anxiety and depression scores of pregnant women between countries affected by the COVID-19 pandemic. The secondary aim is to assess demographic, economic, and social aspects affecting maternal anxiety and depression scores among pregnant women worldwide in the time of the COVID-19 pandemic. Finally, investigators will be able to compare differences in perception of the different aspects of the COVID-19 pandemic (social distancing, restrictions related to delivery) between countries and according to the epidemic status (number of infected patients, number of reported deaths). The comparisons will also be done according to COVID-19 status of the participants.

    NCT04377412
    Conditions
    1. Anxiety
    2. Depression
    3. Pregnancy Related
    Interventions
    1. Other: Pandemic control measures
    MeSH:Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity

    Primary Outcomes

    Description: Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points

    Measure: Anxiety

    Time: 4 months

    Description: Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points

    Measure: Depression

    Time: 4 months
    10 A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic

    The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.

    NCT04384965
    Conditions
    1. Major Depressive Disorder
    Interventions
    1. Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
    MeSH:Depressive Disorder Depressive Disorder, Major
    HPO:Depressivity

    Primary Outcomes

    Description: Less than or equal to 10

    Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Secondary Outcomes

    Description: changes in scores

    Measure: Change in HRSD-24

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score

    Measure: Response on HRSD-24

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4

    Measure: Remission on Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score

    Measure: Response on PHQ-9

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change in PHQ-9

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4

    Measure: Remission on General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score

    Measure: Response on GAD-7

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change in GAD-7

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 12

    Measure: Remission on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in Score

    Measure: Response on BDI-II

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change on BDI-II

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Score of 0

    Measure: Remission on Beck Scale for Suicidal Ideation (SSI)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change on SSI

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change in WHO Disability Assessment Schedule (WHODAS)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Includes number of treatment days needed and number going on to receive ECT

    Measure: Proportion of Patients Maintaining Response During Relapse Prevention

    Time: 24 weeks (Tapering and Relapse prevention phase)
    11 Impact of COVID-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution

    It is aimed to investigate the depression and quality of life of Turkish society caused by Covid-19 pandemic and reveal the relationship between them

    NCT04394078
    Conditions
    1. Depression
    2. Quality of Life
    3. Covid 19
    4. Social Isolation
    Interventions
    1. Other: Online survey
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: Participants are asked to give information about: age, gender, educational status, height, weight, occupation, working status, city inhabited, whether they live alone or with someone, whether they have a chronic disease, have a pet, do physical activity, eat healthy and sufficient, have qualified sleep, whether they are supported economically.

    Measure: Sociodemographic information form

    Time: two months after Covid 19 recognised as pandemic

    Description: Zung depression scale, developed by Zung (Zung, 1965), is patient rating depression scale, was used to asses four domains related to depression; somatic, mood disorders, psychomotor and psychological disorders. Each question is rated on a 4-point Likert scale (0- never, 1- sometimes, 2- frequently, 3- always). Scale contains 10 straight 10 reverse questions. The total score is calculated from the raw score obtained (total score = (raw score / 80) * 100). Accordingly, scores less than 50 are normal or no psychopathology; between 50 and 59 points indicates mild level, between 60 and 69 points indicate moderate level and 70 and above points indicate severe level depression (Thurber et al., 2002). The validity reliability of the scale was studied on Turkish society (Gencdogan & Nihal, 2011)

    Measure: Zung Depression Scale

    Time: two months after Covid 19 recognised as pandemic

    Description: World Health Organization Quality of Life Bref is the short version of the WHOQOL-100 to assess the health-related quality of life (Harper et al., 1998), which has efficient psychometric properties, valid and reliable for Turkish society (Eser et al., 1999). It is essential for epidemiological survey and international report has built for psychometric properties for 26 country where Turkey within (Skevington et al., 2004). It has 4 domains; physical health, psychology, social relations and environment. Each question is answered on a 5-point Likert scale. The raw score is converted into a percentage system. The quality of life is interpreted as good as it gets closer to 100% (Akvardar et al., 2006).

    Measure: World Health Organization Quality of Life - Bref

    Time: two months after Covid 19 recognised as pandemic
    12 dePression, Anxiety, aNd acaDemic pErforMance In Covid-19: PANDEMIC Study.

    This study aims to identify the preference of the class modalities (classroom or online) in undergraduate and graduate students. Additionally, to explore if the presence of any mental state alterations such as depression or anxiety due to the COVID-19 pandemic can alter their perception of academic performance.

    NCT04420416
    Conditions
    1. Depression, Anxiety
    Interventions
    1. Other: Survey
    MeSH:Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity

    Primary Outcomes

    Description: This scale will explore the effort and confidence of the participants. The minimum score for each facet is 10, and the maximum score is 70.

    Measure: Academic Self-Concept Scale Score

    Time: up to 3 months

    Description: This inventory will be used to identify the presence and intensity of depressive disorders. The minimum score is 0, and the maximum score is 27.

    Measure: PHQ-9 Score

    Time: up to 3 months

    Description: This questionnaire will be used to evaluate the presence and intensity of anxiety disorders. The minimum score is 0, and the maximum score is 21.

    Measure: GAD-7 Score

    Time: up to 3 months

    Description: Students' preference of classroom or online classes.

    Measure: Preference of teaching method

    Time: up to 3 months

    Description: Students' perception of changes in their academic performance: got better, worse, or stayed the same.

    Measure: Self perceived academic performance

    Time: up to 3 months

    Description: Students' perception of changes in their grades: got better, worse, or stayed the same.

    Measure: Academic grades changes

    Time: up to 3 months
    13 A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol as a Substitute for Patients With Bipolar Depression Needing Electroconvulsive Therapy During the COVID-19 Pandemic

    The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose LFR protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with bipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.

    NCT04427137
    Conditions
    1. Bipolar Depression
    Interventions
    1. Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
    MeSH:Depression Depressive Disorder Bipolar Disorder
    HPO:Bipolar affective disorder Depressivity Mania

    Primary Outcomes

    Description: Less than or equal to 10 This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Secondary Outcomes

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change in Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of mania Scale range: 0-60 (total score) Lower scores indicate lower severity of manic symptoms (i.e., better outcome) Higher scores indicate higher severity of manic symptoms (i.e., worse outcome)

    Measure: Change in Young Mania Rating Scale (YMRS)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Remission on Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change in Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Remission on General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Response on General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Change in General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 12 This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Remission on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in Score This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Score of 0 This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)

    Measure: Remission on Beck Scale for Suicidal Ideation (SSI)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)

    Measure: Change on Beck Scale for Suicidal Ideation (SSI)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change in WHO Disability Assessment Schedule (WHODAS) Range 0-38

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Includes number of treatment days needed and number going on to receive ECT

    Measure: Proportion of Patients Maintaining Response During Relapse Prevention

    Time: 24 weeks (Tapering and Relapse prevention phase)
    14 Effectiveness of a Healthy Lifestyle Promotion Program as Adjunctive Teletherapy for Treatment-resistant Major Depression During Covid 19 Pandemic: A Randomized Clinical Trial Protocol

    The main objective of the study will be to evaluate the effectiveness of an adjuvant lifestyle-based intervention for treatment-resistant patients with major depressive disorder. Patients will be allocated to one of these three groups: 1)Treatment prescribed by their mental health team plus written lifestyle change suggestions 2)Treatment prescribed by their mental health team plus written lifestyle change suggestions plus 8-week Mindfulness-based cognitive therapy (MBCT) program 3) Treatment prescribed by their mental health team plus written lifestyle change suggestions plus 8-week lifestyle change promotion program. We will collect patient data using the questionnaires administered at baseline, immediately after the intervention, and at six and 12-month follow-up. The primary outcome will be depression severity and secondary outcomes will include health-related quality of life.

    NCT04428099
    Conditions
    1. Depressive Disorder, Treatment-Resistant
    Interventions
    1. Behavioral: Lifestyle change promotion program
    2. Behavioral: Mindfullness based cognitive program
    3. Behavioral: Written Information
    MeSH:Depressive Disorder Depressive Disorder, Treatment-Resistant
    HPO:Depressivity

    Primary Outcomes

    Description: Beck Depression Inventory-II (BDI-II)

    Measure: Depression severity

    Time: 12 month

    Secondary Outcomes

    Description: Questionnaire (EQ-5D)

    Measure: Health-related quality of life

    Time: 12 month
    15 Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia

    The aim of this multicenter prospective study is to evaluate the association between the Covid-19 pandemic maternal psychological distress with the postpartum depression, demographic and anaesthesiologic variables

    NCT04437342
    Conditions
    1. Postpartum Depression
    2. Psychological Stress
    3. Maternal Distress
    Interventions
    1. Other: PHQ-9 (Patient Health Questionnaire) Depression Scale
    2. Other: GAD-7 (General Anxiety Disorder) scale
    3. Other: 38 questions questionnaire
    4. Other: EPDS (Edinburgh Postnatal Depression Scale)
    MeSH:Depression, Postpartum Depression Depressive Disorder Stress, Psychological
    HPO:Depressivity

    Primary Outcomes

    Description: Prevalence of postpartum depression during the Covid-19 pandemic with EPDS scale (Edinburgh postnatal depression scale)

    Measure: Correlation between the Covid-19 pandemic and postpartum depression with EPDS scale (Edinburgh postnatal depression scale)

    Time: 40 days postpartum

    Secondary Outcomes

    Description: Association between the Covid-19 pandemic, postpartum depression and type of anaesthesia (general, epidural, spinal, combined, epidural analgesia for vaginal delivery)

    Measure: Correlation between the Covid-19 pandemic, postpartum depression and type of anaesthesia (general, epidural, spinal, combined, epidural analgesia for vaginal delivery)

    Time: 10 minutes postpartum

    Description: Association between the Covid-19 pandemic, postpartum depression and postpartum pain assessed during postanesthesia care unit stay assessed by Numeric Pain Rating Scale (Scale 0-10 where 0 equals no pain and 10 maximum possible pain)

    Measure: Correlation between the Covid-19 pandemic, postpartum depression and postpartum pain

    Time: 2 minutes prior to discharge from the Postanaesthesia care unit

    Description: Association between the Covid-19 pandemic, postpartum depression and postpartum pain assessed during postanesthesia care unit stay assessed by Numeric Pain Rating Scale (Scale 0-10 where 0 equals no pain and 10 maximum possible pain)

    Measure: Correlation between the Covid-19 pandemic, postpartum depression and postpartum pain

    Time: 2 minutes after admission to the Postanaesthesia care unit
    16 Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic

    Study description: The present study seeks to investigate the predictors and maintaining mechanisms of depression and anxiety symptoms during the COVID-19 pandemic, exactly 3 months following the strictest viral mitigation strategies initiated in Norway in response to the pandemic. This is the time period where the major pandemic protocols are lifted in Norway, following three months of strict pandemic mitigation protocols. The study further aims to identify subgroups with highest levels of depressive and anxiety symptoms during the measurement period, to identify vulnerable subgroups with maintained symptoms three months following the pandemic. Hypotheses and research questions: Research Question 1: What is the level of depressive and anxiety symptoms three months following the employment of the strict viral mitigation protocols (i.e., physical distancing protocols) in the general adult population? What are the proportion above the validated cut-offs for depression and general anxiety? Hypothesis 1: There will be a significant decrease in the levels of depression and anxiety symptoms from the baseline (T1) with the strictest mitigation protocols to measurement the measurement period three months into pandemic (T2) where major pandemic mitigation protocols are lifted. Additionally, there will be a significant decrease in the proportion of the sample meeting validated cut-offs for depression and anxiety from T1 to T2. Hypothesis 2: Higher level at T1 and less reduction from T1 to T2 in positive metacognitions, negative metacognitions, and unhelpful coping strategies all measured with CAS-1, will be related to less reduction in depression and anxiety, above and beyond age, gender, and education. Higher level at T1 and increases from T1 to T2 in physical activity and perceived competence will be related to greater reduction in depression and anxiety, above and beyond, age, gender, and education. Exploratory: The investigators will further explore the proportion showing reliable change in depression and anxiety and investigate the differences in changes in depression and anxiety across different demographic subgroups in the sample

    NCT04442204
    Conditions
    1. Depression
    2. Anxiety
    Interventions
    1. Other: Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
    MeSH:Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity

    Primary Outcomes

    Description: • The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.

    Measure: Patient Health Questionnaire 9

    Time: Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks.

    Description: • The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).

    Measure: Generalized Anxiety Disorder 7

    Time: Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks.
    17 Prevalence of Mental Health Problems Among Undergraduate Students at the Universidad de Los Andes

    This project seeks to know the prevalence of mental health problems among undergraduate students, through internationally and nationally validated screening instruments. The project also aims to understand better the associated factors contributing to the mental health problems of this population. Through the critical analysis of the results, our proposal aims to establish the prevalence of anxiety, depression, suicidality and substance use, and the association with socioeconomic features, academic stress, sense of belonging to the university, interpersonal relationships, and sleep habits among other factors. Once finalized the study, the results obtained will be disseminated to the university community and published in peer-reviewed journals. The results will help the university authorities to design and implement measures to prevent mental health problems in this community.

    NCT04447690
    Conditions
    1. Student
    2. Mental Health
    3. Depression, Anxiety
    4. Depression
    5. Anxiety
    6. College Drinking
    7. Stress
    MeSH:Depression Depressive Disorder Anxiety Disorders Alcohol Drinking in College
    HPO:Depressivity

    Primary Outcomes

    Description: Self-reported symptoms with the Depression, Anxiety and Stress Scale (DASS-21), which have 21 items, each scoring between 0 and 3, the minimum score is 0 and the maximum score of 63. The cut-off score for the depression subscale is 6, Anxiety is 5, Stress is 6.

    Measure: Depression, Anxiety and Stress Scale (DASS-21)

    Time: Up to 4 weeks

    Description: The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment. This scale has 6 items and each item has to be answered Yes or No. The total score is 6. A score of 0 is no ideation is present.

    Measure: Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time: Up to 4 weeks

    Description: Self-report of harmful alcohol drinking. 4 items. CAGE stands for: C: Have you felt the need to Cut down drinking? A: Have you ever felt Annoyed by criticism of drinking? G: Have you had Guilty feelings about drinking? E: Do you ever take a morning Eye opener (a drink first thing in the morning to steady your nerves or get rid of a hangover)? The range score goes from 0 to 4. The point cut off is >= 2.

    Measure: CAGE

    Time: Up to 4 weeks

    Description: Adaptation of The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) interview model, including prescription and nonprescription drugs and vaping. It has 8 items exploring the frequency of substance use in the last 3 months (daily, weekly, yearly) and the problems associated with the use. It explores the use of 10 kinds of drugs.

    Measure: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

    Time: Up to 4 weeks

    Secondary Outcomes

    Description: Ad hoc self-report survey: Current age University enrollment year Current years of study Sex Gender Civil status Parenting and number of child(s) Nationality Etnicity Ocupational situation: only study, part-time worker, fulltime worker and study Carrer Maximum parents studies degree: analphabet, school, undergraduate, postgraduate; complete or incomplete studies. Payment of studies: credit, schollarship, self-pay Travel time from home to campus: minutes, hours.

    Measure: Sociodemographic characteristics

    Time: Up to 4 weeks

    Description: Self-perception on a subjective analogous scale of physical health

    Measure: General Health perception

    Time: Up to 4 weeks

    Description: Self-perception on a subjective analogous scale of mental health

    Measure: General Menta Health perception

    Time: Up to 4 weeks

    Description: Ad hoc self-report survey of any previous chronic physical disease

    Measure: History of chronic diseases

    Time: Up to 4 weeks

    Description: Ad hoc self-report survey of minutes of physical activity during the past week

    Measure: Physical activity

    Time: Up to 4 weeks

    Description: Ad hoc self-report survey of time spent with friends or social gatherings

    Measure: Social activities

    Time: Up to 4 weeks

    Description: Family functionality APGAR score: a 5-item measure of perceived family support in the domains of adaptation, partnership, growth, affection, and resolve. E.g. "I find that my family accepts my wishes to take on new activities or make changes in my lifestyle". Scores range from 0 to 10, being 10 a total satisfaction with family functionality.

    Measure: Family functionality (APGAR)

    Time: Up to 4 weeks

    Description: Ad hoc self-report questionnaire of personal and family mental health history: Previous diagnosis of depression, bipolar disorder, panic attacks, anxiety disorders, eating disorders, ADHD. Current psychotherapy of psychiatric medication Family history of psychiatric disorders

    Measure: History of personal and family mental health problems

    Time: Up to 4 weeks

    Description: Self-report of insomnia perception. it has 7 items, and responses can range from 0 to 4, where higher scores indicate more acute symptoms of insomnia. Scores ranges from 0 to 28. A clinical Insomnia threshold score of 15.

    Measure: Insomnia Severity Index (ISI)

    Time: Up to 4 weeks

    Description: Ad hoc self-report survey of violence suffered from teachers, administrative, auxiliaries, and other students; discrimination and bullying.

    Measure: University violence and bullying

    Time: Up to 4 weeks

    Description: Ad hoc self-report survey of sexual health, including sexual orientation, the current status of an emotional relationship, number of sex partners in the last year, history of Sexually Transmitted Disease (STD).

    Measure: Sexuality and sexual health

    Time: Up to 4 weeks

    Description: Sense of Social and Academic Fit (SSAF) is a self-report questionnaire of 17 items, with responses on a Likert format from 1-7. It measures academic and social sense of belonging. The score is produced as the average of the scores reported in each item. The minimum score is 1 and the maximum score is 17. A higher score means higher sense of belonging.

    Measure: Sense of Social and Academic Fit (SSAF)

    Time: Up to 4 weeks

    Description: Ad-hoc self-report survey of current perception and possible diagnosis of COVID-19: Fear or preoccupation about getting COVID-19 Sense of severity if diagnosed with COVID-19 Fear or preoccupation about a family member or friend to get COVID-19 Current diagnosis of COVID-19 A family member diagnosed with COVID19 Sense of compliance with social isolation and quarantine Persons living with (family, friends, alone) Frequency of: going out of home, gather with others, virtual socialization, keeping a routine, exercise realized, recreative activities, meditation or prayer, seek information about the situation of COVID19 Frequency of the following symptoms: nervousness, hopelessness, depression, amount of effort required to realize activities, self-value, anhedonia.

    Measure: COVID-19 questions

    Time: Up to 4 weeks
    18 Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Naturalistic Cohort Study With a Digital Intervention

    Studies have shown that admission to hospital during a coronavirus epidemic is associated with increased levels of anxiety, depression and panic disorder. During the SARS-CoV-2 pandemic in North London the Royal Free Hospital admitted over 500 patients with Covid-19. As part of the standard of care, these patients are screened at 8 weeks post discharge for signs of anxiety and depression. The Feeling Good app is a NHS approved digital application which utilises applied relaxation, mindfulness based cognitive therapy and positive visualisation through audio tracks for the treatment of anxiety and depression. This is a naturalistic cohort study aimed to track the post illness psychological symptoms of those who have been admitted with Covid-19 to the Royal Free hospital up to 5-7 months after discharge. The study population is those who are exhibiting anxiety or depressive symptoms as measure by the PHQ-2 or TSQ questionnaires. All those with symptoms will be offered free access to a NHS approved app for anxiety and depression, and followed up for 3 months after recruitment to track changes to their symptoms.

    NCT04449627
    Conditions
    1. Anxiety Disorders
    2. Post Traumatic Stress Disorder
    3. Depressive Disorder
    4. Covid19
    Interventions
    1. Other: Feeling Good Digital App
    MeSH:Disease Depressive Disorder Stress Disorders, Traumatic Anxiety Disorders Stress Disorders, Post-Traumatic
    HPO:Depressivity

    Primary Outcomes

    Description: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.

    Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale

    Time: Day 14

    Secondary Outcomes

    Description: The Patient Health Questionnaire (PHQ-9) is a screening tool for the identification of depressive disorders, which has been validated for use in primary care. Each of the nine items in the questionnaire is based on the DSM diagnostic criteria for clinical depression. The PHQ-9 is scored out of 27 according to severity, where score of 5-9 indicates mild depression, 10-14 moderate, 15-19 moderately severe, and 20 or above severe depression.

    Measure: Depression as measured by the patient health questionnaire 9 (PHQ-9)

    Time: 14 days and week 12

    Description: The Trauma screening questionnaire (TSQ) is a 10 point scale used to identify symptoms of post traumatic stress disorder (PTSD), with a score between 0 and 10, with a score of 6 or higher scored as positive.

    Measure: Trauma as measured by Trauma screening questionnaire (TSQ)

    Time: 12 weeks

    Description: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.

    Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale

    Time: Week 12

    Other Outcomes

    Description: Risk factors for psychological distress from admission with Covid-19 will be collected, these will include, age, gender, ethnicity, length of hospital stay, oxygen requirement, co-morbidites, years of education, smoking status, occupation.

    Measure: Risk associated with distress

    Time: Baseline analysis

    Description: Framework analysis. Qualitative feedback of patient experience. Semi structured interviews of a subset of patients will be performed to gain further insight into the patient experience. These will be analysed using a framework thematic analysis, to identify themes which will then be used to code the text.

    Measure: Qualitative analysis

    Time: Baseline
    19 Effectiveness of a Self-applied Positive Psychology Online Intervention Program "Mental Health COVID-19" in Mexican Population: A Randomized Controlled Trial.

    This study evaluates the effectiveness of a Positive Psychology intervention, that is focused on increasing the positive emotions and strengths of human beings. It is compared to the effectiveness of an online treatment with the change of the same participants before and after receiving the treatment accompanied by a chat support service vs. the treatment solely. The changes are being assessed through worldwide validated measures such as psychometrics.

    NCT04468893
    Conditions
    1. Anxiety
    2. Depression
    3. Sleep Disturbance
    Interventions
    1. Behavioral: Online Intervention Mental Health COVID-19
    MeSH:Dyssomnias Parasomnias Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: The State/Trait Anxiety Inventory consists of two subscales of 20 items each that measure anxiety as a transient state of tension (Scale A-State), and as a characteristic of the personality relatively stable over time (Scale B -trait). The items are composed by an assertion to which the subject responds indicating their degree of identification. In the case of state anxiety, the scale goes from 1 (not at all), 2 (somewhat), 3 (moderately), 4 (very much), while in the trait anxiety it ranges from 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). In both, a percentage of the items evaluate well-being or absence of anxiety, while the rest of the items to the presence of anxiety. Scores range from 20 to 80, in each subscale, with higher scores correlating with greater anxiety. It is expected a statistically significant decrease (P < 0.05) in the anxiety symptoms.

    Measure: Decrease in the score of Anxiety symptoms

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Description: The Beck Depression Inventory is a self-report that provides a measure of the presence and severity of depression. Contains 21 items indicative of symptoms such as sadness, crying, loss of pleasure, feelings of failure and guilt, suicidal thoughts or desires, pessimism, etc. Each item is answered on a 4-point scale, from 0 to 3, where each number is identified differently for each item, in all of them 0 means absence and 3 full presence (e.g. sadness), except for items 16 (changes in the sleep pattern) and 18 (changes in appetite) that contain 7 categories. The minimum and maximum scores in the test are 0 and 63. Cut-off points ha that allow classifying those evaluated in one of the following four groups: 0-13, minimum depression; 14-19, mild depression; 20-28, moderate depression; and 29-63, severe depression. It is expected a statistically significant decrease (P < 0.05) in the depression symptoms.

    Measure: Change in the symptoms of depression

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Description: On the Generalized Anxiety Disorder 7-item (GAD-7) scale subjects are asked how often, during the last 2 weeks, they have been bothered by each of the 7 core symptoms of generalized anxiety disorder. Response options are "not at all," "several days," "more than half the days," and "nearly every day," scored as 0, 1, 2, and 3, respectively. Therefore, GAD-7 scores range from 0 to 21, with scores of ≥5, ≥10, and ≥15 represent mild, moderate, and severe anxiety symptom levels, respectively. It is expected a statistically significant decrease (P < 0.05) in the General Anxiety symptoms.

    Measure: Change in the symptoms of General Anxiety Disorder

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Description: The Scale of Post-traumatic Stress Traits in the Mexican Youth Exposed to Social Violence It is a brief scale with 24 symptoms corresponding to the diagnosis of PTSD, to respond by self-report, and a scale was used discretely from 1 (strongly disagree) to 4 (strongly agree). The total score was obtained by arithmetic sum. The minimum possible is 24 and the maximum 96. It is expected a statistically significant decrease (P < 0.05) in the posttraumatic stress symptoms.

    Measure: Change in the score of Posttraumatic stress symptoms

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Description: It is composed of seven items with options of 0 = nothing, 3 = a lot, and measures the fear in its emotional component, that is, the fear to adversities in the context and the feelings it disseminates, as well as others economic and social fears, in this case, adapted for the Sars-Cov2 pandemic. In previous studies, an acceptable internal consistency of .95 was reached. It consists of several items about the fear of being a SARS Cov2 victim in diverse contexts. In the present study, a Cronbach alpha coefficient of 0.96 was obtained. It is expected a statistically significant decrease (P < 0.05) in the widespread fear symptoms.

    Measure: Changes in the Widespread fear Scale

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Description: This instrument assesses the quality patterns of sleep. It differentiates the "poor" and "good" sleep by measuring seven areas, where the range score of answers are from 0 to 3, the global sum of this scale can be a value between 0 to 60, and the cutoff point is "5" that indicates a "poor" sleep quality. It is expected a statistically significant increase (P < 0.05) in the Sleep Quality Index.

    Measure: Change in the score of The Pittsburgh Sleep Quality Index.

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]

    Secondary Outcomes

    Description: This scale aims to assess the frequency of attitudes, behaviors and plans to commit suicide. It is divided into 19 items with a response option of 0 to 2, giving a total of 0 to 38 where a score equal to or greater than 10 indicates an existing risk of suicide. This scale has been validated in the Mexican population (González-Macip & Díaz-Martínez, 2000).

    Measure: Change on the Suicidal Thoughts Scale

    Time: [Time Frame: 2 weeks to one month, depending on the development of the patient and the completion of the 15 modules.]
    20 Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

    Postpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.

    NCT04487171
    Conditions
    1. Postpartum Depression
    2. Covid19
    3. Prevalence
    4. Social Distance
    Interventions
    1. Other: Questionnaire
    MeSH:Depression, Postpartum Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: Variation of prevalence of clinically-significant post-partum depressive symptoms

    Measure: Variation of prevalence of clinically-significant post-partum depressive symptoms

    Time: up to 35 days after delivery
    21 Scaling Mental Healthcare in COVID-19 With Voice Biomarkers: An Observational Study

    This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and developing workflows for mental health that are both scalable and personalized.

    NCT04510519
    Conditions
    1. Major Depressive Disorder
    2. Generalized Anxiety
    MeSH:Depressive Disorder Depressive Disorder, Major
    HPO:Depressivity

    Primary Outcomes

    Description: A repeated measures, within-subject design using exploratory techniques will identify the best group session features or combination of features that correlate with or predict change on the PHQ-9.

    Measure: Patient Health Questionnaire (PHQ-9)

    Time: March 30, 2021

    Description: A repeated measures, within-subject design using exploratory techniques will identify the best group session features or combination of features that correlate with or predict change on the GAD-7.

    Measure: Generalized Anxiety Disorder (GAD-7)

    Time: June 20, 2021
    22 Survey About Anxious and Depressive Symptoms During COVID-19 in Women Who Have Medical History of Post-partum Depression: Interest of Tele-consultation

    Women who were able to benefit from psychiatric follow-up during the quarantine by tele-consultation have a lower risk of anxious and depressive symptoms than those who did not receive follow-up.

    NCT04516668
    Conditions
    1. Post Partum Depression
    MeSH:Depression, Postpartum Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: To compare depression and anxiety HAD score of women who have a medical history ofpost-partum depression according to a follow-up or not during the quarantine by tele-consultation Score less than or egal to 7 = no case Score between 8 and 10 = uncertain case Score higher than or equal to 11 = confirmed case

    Measure: Evaluation of Hospital anxiety and depression scale (HAD)

    Time: 15 minutes

    Secondary Outcomes

    Description: To compare the result of EPDS in women who have a child of less 2 years old according to a follow-up or not by tele-consultation during the quarantine

    Measure: Evaluation of Edinburgh Postpartum Depression Scale (EPDS)

    Time: 15 minutes

    Description: Anxiety and depression of fathers will be assessed with HAD scale

    Measure: Evaluation of HAD score in fathers

    Time: 15 minutes

    Description: EPDS will be assessed in fathers who have a child of less than 2 years old

    Measure: Evaluation of EPDS in fathers

    Time: 15 minutes

    Description: The aim is to show that maternals anxious and depressive symptoms would be correlated to paternals positively symptoms

    Measure: Study of the relationship between maternals and paternals symptoms

    Time: 15 minutes

    Description: Look for a correlation between the difficulties in child during the quarantine describe by parents and anxiety and depression symptoms in parents The difficulties in child will be illustrated with the rate of children with difficulties describe by the parents

    Measure: Study of difficuties in child during the quarantine

    Time: 15 minutes

    Description: Description of risk factors and protection factors setting up by the family during this quarantine period

    Measure: Risk and protection factors

    Time: 15 minutes
    23 Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19

    Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social and family relationships, substance abuse, and worsening of other health conditions, which can persist into adulthood. Access to mental health care for teenagers is limited due to a shortage of mental health providers and many teenagers and parents are reluctant to take antidepressants. COVID-19 and mandated physical and social distancing is expected to increase rates of teenage depression, and further limit access to traditional methods of care (e.g. psychotherapy). This highlights an urgent need to develop accessible, digital treatments for teenage depression to address the serious mental health impacts of the COVID-19 pandemic. This fully virtual study (https://www.limbix.com/spark) will compare the relative safety, effectiveness, and engagement of a mobile application based on cognitive behavioral therapy and behavioral activation (Limbix Spark), focusing on the idea that engaging in behaviors that are rewarding or provide a sense of mastery can be effective in reducing symptoms of depression. Limbix Spark will be compared to a mobile app containing educational material about depression (Psychoeducation).

    NCT04524598
    Conditions
    1. Depression
    Interventions
    1. Device: Limbix Spark
    2. Other: Psychoeducation
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).

    Measure: Change in depressive symptoms

    Time: Change from Baseline to Post treatment (5 weeks)

    Secondary Outcomes

    Description: Change in anxiety symptoms measured by the Generalized Anxiety Disorder (GAD-7) scale (min: 0; max: 21, with higher score indicating more severe anxiety).

    Measure: Change in anxiety symptoms

    Time: Change from Baseline to Post treatment (5 weeks)

    Description: Change in parent report of child depressive symptoms measured by the Mood and Feelings Questionnaire (MFQ) (min: 0; max: 26, with higher score indicating more severe depression)

    Measure: Change in parent report of child depressive symptoms

    Time: Change from Baseline to Post treatment (5 weeks)
    24 Depression, Anxiety and SARS-CoV-2 Phobia in Post-stroke Patients During SARS-CoV-2 Pandemic

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.

    NCT04560413
    Conditions
    1. SARS-CoV-2
    2. Post-stroke Depression
    3. Anxiety and Fear
    MeSH:Stroke Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity Stroke

    Primary Outcomes

    Description: The Hospital Anxiety and Depression Scale evaluation includes a total of 14 questions (score range 0-3), which are scored to separately estimate anxiety and depressive status (7 questions each). The individual score for the anxiety and depression subscales may vary from 0 to 21. The aim of this scoring system is not to make an objective diagnosis, but to determine the current presence and tendency to anxiety or depression at the time of diagnosis. A HADS score of 8 to 10 is broadly accepted as indicating mild symptoms, a score between 11-16 suggests moderate anxiety or depression, and a score of 16 or more indicates severe anxiety or depressive symptoms

    Measure: Hospital Anxiety and Depression Scale

    Time: 3 months

    Description: The Covid 19 Phobia Scale is a self-report instrument with a five-point Likert-type scale to assess the levels of SARS-CoV-2 phobia. All items are rated on a 5-point scale from "strongly disagree (1)" to "strongly agree (5)." The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales and total scale. In the present study total scale scores ranged from 20 to 100. The scale examines four main factors: psychological, psycho-somatic, economic and social

    Measure: Covid 19 Phobia Scale

    Time: 3 months
    25 Symptoms of Depression, Stress and Burnout, and Long-term Psychological Impact in Health Care Professionals Exposed to the Novel Coronavirus Disease 2019 Outbreak (HARD-COVID-19 - Health cAre woRkers exposeD to covID-19)

    Hospital health workers involved in the coronavirus epidemic are facing several challenges such as direct exposure and involvement in the resolution of major public health emergencies, exposure to potentially fatal contamination, physical exhaustion , unadjusted work organizations, the unusual number of deaths among patients, colleagues and close relatives, and significant ethical challenges in decision-making. Preliminary data suggests that frontline and lay professionals suffer from different types of psychological distress. These data highlight the importance of screening for psychological distress in response to the scale of the pandemic and the provision of targeted psychological interventions, such as Eye Movement Desensitization and Reprocessing (EMDR, desensitization and neuro-emotional integration by eye movements), to improve the psychological well-being of healthcare workers exposed to COVID-19. This project is both a cohort study with the proposal of a randomized trial to evaluate an intervention adapted to the exceptional circumstances of the crisis. As such, it is designed as Trial(s) Within Cohort design (TWIC).

    NCT04570202
    Conditions
    1. Depression
    2. Burnout, Professional
    3. Post Traumatic Stress Disorder
    Interventions
    1. Behavioral: EMDR
    MeSH:Burnout, Professional Depression Depressive Disorder Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Burnout, Psychological
    HPO:Depressivity

    Primary Outcomes

    Description: This study is investigating three different conditions (PTSD, Depression and Burnout) each assessed with its own primary endpoint. Thus, the trial will have three primary endpoints. Change over a 6 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5). The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.

    Measure: Efficacy on symptoms of Post-Traumatic Stress Disorder

    Time: From inclusion to 6 months after inclusion

    Description: Change over a 6 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL). The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.

    Measure: Efficacy on symptoms of Burnout

    Time: From inclusion to 6 months after inclusion

    Description: Change over a 6 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.

    Measure: Efficacy on symptoms of Depression

    Time: From inclusion to 6 months after inclusion

    Secondary Outcomes

    Description: Change over a 3 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5). The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.

    Measure: Short-term efficacy on symptoms of PTSD

    Time: From inclusion to 3 months after inclusion

    Description: Change over a 3 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL). The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.

    Measure: Short-term efficacy on symptoms of Burnout

    Time: From inclusion to 3 months after inclusion

    Description: Change over a 3 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.

    Measure: Short-term efficacy on symptoms of Depression

    Time: From inclusion to 3 months after inclusion

    Description: Change over a 12 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5) for the participants who will be enrolled in the trial at M0 of the cohort. The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.

    Measure: Long-term efficacy on symptoms of PTSD

    Time: From inclusion to 12 months after inclusion

    Description: Change over a 12 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL) for the participants who will be enrolled in the trial at M0 of the cohort. The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.

    Measure: Long-term efficacy on symptoms of Burnout

    Time: From inclusion to 12 months after inclusion

    Description: Change over a 12 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9) for the participants who will be enrolled in the trial at M0 of the cohort. The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.

    Measure: Long-term efficacy on symptoms of Depression

    Time: From inclusion to 12 months after inclusion

    Description: Change over a 6 months period in anxiety measured by the Generalized Anxiety Disorder-7 questionnaire (GAD-7). The GAD-7 score is on a scale from 0 to 21. The higher the score, the higher the level of anxiety symptoms are.

    Measure: Efficacy on symptoms of Anxiety

    Time: From inclusion to 6 months after inclusion

    Description: Change over a 12 months period in anxiety measured by the Generalized Anxiety Disorder-7 questionnaire (GAD-7) for the participants who will be enrolled in the trial at M0 of the cohort. The GAD-7 score is on a scale from 0 to 21. The higher the score, the higher the level of anxiety symptoms are.

    Measure: Long-term efficacy on symptoms of Anxiety

    Time: From inclusion to 12 months after inclusion

    Description: Number of suicide attempts over a 6-month period from baseline

    Measure: Efficacy on suicide attempts

    Time: From inclusion to 6 months after inclusion

    Other Outcomes

    Description: Changes in the level of suicidal ideation over a 6 months period from baseline measured by Visual Analog Scale (VAS). The VAS is on a scale from 0 to 10. The higher the VAS score, the higher suicidal ideation level is.

    Measure: Efficacy on suicidal ideation

    Time: From inclusion to 6 months after inclusion

    Description: Changes in the level of suicidal ideation over a 12 months period from baseline measured by Visual Analog Scale (VAS) for the participants who are enrolled in the trial at M0 of the cohort. The VAS is on a scale from 0 to 10. The higher the VAS score, the higher suicidal ideation level is.

    Measure: Long-term efficacy on suicidal ideation

    Time: From inclusion to 12 months after inclusion

    Description: Change in the impact of health on functioning (Role Emotional (RE) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 6 months period from baseline. The RE score is on a scale from 0 to 100. The higher the score, the better Role Emotional is.

    Measure: Efficacy on the impact of health on functioning: Role Emotional

    Time: From inclusion to 6 months after inclusion

    Description: Change in the impact of health on functioning (Role Emotional (RE) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 12 months period from baseline for the participants who are enrolled in the trial at M0 of the cohort. The RE score is on a scale from 0 to 100. The higher the score, the better Role Emotional is.

    Measure: Long-term efficacy on the impact of health on functioning: Role Emotional

    Time: From inclusion to 12 months after inclusion

    Description: Change in the impact of health on functioning (Role Physical (RP) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 6 months period from baseline. The RP score is on a scale from 0 to 100. The higher the score, the better Role Physical is.

    Measure: Efficacy on the impact of health on functioning: Role Physical

    Time: From inclusion to 6 months after inclusion

    Description: Change in the impact of health on functioning (Role Physical (RP) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 12 months period from baseline for the participants who are enrolled in the trial at M0 of the cohort. The RP score is on a scale from 0 to 100. The higher the score, the better Role Physical is.

    Measure: Long-term efficacy on the impact of health on functioning: Role Physical

    Time: From inclusion to 12 months after inclusion

    Description: Evolution of substance use over 6 months

    Measure: Substance use

    Time: From inclusion to 6 months after inclusion

    Description: Evolution of substance use over 12 months for the participants who are enrolled in the trial at M0 of the cohort

    Measure: Long-term substance use

    Time: From inclusion to 12 months after inclusion

    Description: Evolution of medication use over 6 months

    Measure: Medication use

    Time: From inclusion to 6 months after inclusion

    Description: Evolution of medication use over 12 months for the participants who are enrolled in the trial at M0 of the cohort

    Measure: Long-term medication use

    Time: From inclusion to 12 months after inclusion

    Description: Number of consultations of health professionals within the period of follow-up (general practitioner, psychiatrist, psychotherapist, psychologist, professionals who are practicing alternative medicines); Occurrence of EMDR therapy within the control group; Number of visits at the emergency unit of a hospital; Number of nights spent in hospital as a patient (short-term); Number of nights spent in rehabilitation facilities as a patient.

    Measure: Health care utilization

    Time: From inclusion to 6 months after inclusion

    Description: Number of consultations of health professionals within the period of follow-up (general practitioner, psychiatrist, psychotherapist, psychologist, professionals who are practicing alternative medicines); Occurrence of EMDR therapy within the control group; Number of visits at the emergency unit of a hospital; Number of nights spent in hospital as a patient (short-term); Number of nights spent in rehabilitation facilities as a patient. For the participants who are enrolled in the trial at M0 of the cohort

    Measure: Long-term health care utilization

    Time: From inclusion to 12 months after inclusion

    Description: Proportion of those who will be offered EMDR and will actually receive EMDR

    Measure: Acceptability of EMDR in the EMDR group

    Time: From inclusion to 12 months after inclusion

    Description: Number of sessions attended over the total planned number

    Measure: Compliance in the EMDR group

    Time: From inclusion to 12 months after inclusion
    26 Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use

    This 3-arm study compares the effectiveness of an (1) 8-week mindfulness-based intervention, MBCT-R (Mindfulness-Based Cognitive Therapy for Resilience During COVID-19)+CHA MindWell vs. (2) iCBT (internet based Cognitive Behavioral Therapy)+ CHA MindWell vs. (3) CHA MindWell remote monitoring and telephone coaching alone on depressive symptoms as measured over the course of 24-weeks by the computerized adaptive mental health (CAT-MH) interview for depression (CAT-DI). Secondary outcomes include rates and levels of alcohol and drug use, as well as the number of required mental health clinician visits (televisits and in-person visits). Exploratory outcomes include stress-related affect reactivity and salivary inflammatory markers (e.g., interleukin-6).

    NCT04595084
    Conditions
    1. Depression
    2. Anxiety
    3. Substance Use
    4. Stress, Psychological
    5. Stress, Emotional
    6. Alcohol Use, Unspecified
    7. Drug Use
    8. Covid19
    Interventions
    1. Behavioral: Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell
    2. Behavioral: Internet Cognitive Behavioral Therapy plus CHAMindWell
    3. Behavioral: CHAMindWell
    MeSH:Depression Depressive Disorder Stress, Psychological
    HPO:Depressivity

    Primary Outcomes

    Description: Change in depression symptom severity as measured by CAT-MH Depression Inventory (DI) scores completed at baseline and every 4 weeks during the 24 weeks after randomization. Difference between MBCT-R arm and CHA-MW monitoring alone arm is primary outcome. Difference between iCBT arm and CHA-MW monitoring alone arm is secondary outcome. Difference between iCBT arm and MBCT-R is an exploratory outcome.

    Measure: Depression Severity (CAT-DI)

    Time: Baseline, Weeks 4, 8, 12, 16, 20, 24

    Secondary Outcomes

    Description: Rates of positive toxicology screens for illicit drugs or unprescribed controlled substances at 24 weeks. Rates of positive toxicology for illicit drug use or controlled substances (non prescribed) at week 24 is the secondary outcome.

    Measure: Drug Use Rates

    Time: Week 24

    Description: We will conduct an Alcohol Use History at Week 24. We will conduct 30-day alcohol and substance use history using the TimeLine Follow Back (TLFB) Method at Week 24 visit by telephone or video conference. Heavy Drinking Days in past 30 days is the secondary outcome.

    Measure: Heavy Drinking Days

    Time: Week 24

    Description: Number of mental health clinician televisits during 24 weeks

    Measure: Televisits

    Time: Randomization through Week 24

    Other Outcomes

    Description: Participants report the frequency of emotions using a 5-point scale: 0 = none of the time, 1 = a little of the time, 2 = some of the time, 3 = most of the time, 4 = all of the time. The NA scale consists of 14 items: restless or fidgety, nervous, worthless, so sad nothing could cheer you up, everything is an effort, hopeless, lonely, afraid, jittery, irritable, ashamed, upset, angry, and frustrated. The PA scale consists of 13 items: in good spirits, cheerful, extremely happy, calm and peaceful, satisfied, full of life, close to others, like you belong, enthusiastic, attentive, proud, active, and confident. Daily NA and PA are calculated by averaging the items within each subscale, and then aggregating scores across interview days.

    Measure: Positive and Negative Affect Reactivity Scales

    Time: Weeks -4, -3, -2, -1, 0, 9, 10, 11

    Description: The Daily Inventory of Stressful Events is used to assess whether each of 7 types of stressors occurred in the past 24 hours: argument, avoided an argument, stressor at work or school, stressor at home, discrimination, network stressor (i.e., stressful event that happened to a close friend or family member), and any other stressor. A day is categorized as a "stressor day" if the participant endorsed at least one stressor, or a "nonstressor day" if the participant indicated that no stressors occurred. Stressor frequency is defined as the percentage of interview days during which at least one stressor occurred. Salivary Cytokine Panels will be collected on two of these stressor and non stressor days respectively.

    Measure: Daily Inventory of Stressful Events

    Time: Weeks -4, -3, -2, -1, 9, 10, 11, 12

    Description: Difference between mean level of salivary Interleukin-6 during 2 low stressor and 2 high stressor days is exploratory outcome. Evening salivary passive drool samples (which assess TNF-a, IL-1b and IL-8 in addition to IL-6) will be collected 4 times during weeks -4-0 and 4 times during weeks 9-12 during diary collection. They will be primed with REDCAP branching logic activated by 2 multi-stressor (high) stressor days and 2 no stressor days. REDCAP will specifically tell them to select a color/letter coded sampling contained and they will collect that sample that evening. They will place samples immediately in the freezer.

    Measure: Inflammatory Cytokines (IL-6, IL-1b, IL-8, TNF-a)

    Time: Weeks -4, -3, -2, -1, 9, 10, 11, 12

    Description: A 15-item scale with content from six dimensions of experiential avoidance.

    Measure: Brief Experiential Avoidance Questionnaire (BEAQ)

    Time: Baseline, Weeks 4, 8, 12

    Description: The Difficulties in Emotion Regulation (DERS) Scale is a 36-item self-report scale designed to assess emotional dysregulation using a 5 point Likert scale. The scale assesses 6 aspects of emotional dysregulation: non-acceptance of emotional responses, difficulties engaging in goal directed behavior, impulse control difficulties, lack of emotional awareness, limited access to emotion regulation strategies, and lack of emotional clarity. Subscales are summed and a lower total score represents a better outcome. Individual subscales will also be assessed.

    Measure: Difficulties in Emotion Regulation Scale (DERS)

    Time: Baseline, Weeks 4, 8, 12

    Description: The Perceived Stress Scale (PSS-14) (14 items) measures the degree to which situations in life are stressful. Items are designed to evaluate how overloaded, unpredictable, and uncontrollable one finds one's life. Each item is scored on a 5 point Likert scale from 0 (Never) to 4 (Very often).

    Measure: Perceived Stress Scale (PSS-14)

    Time: Baseline, Weeks 4, 8, 12, 24

    Description: The short-form Self-Compassion Scale (SCS-SF) is an abbreviated 12-item form of the original 26-item Self-Compassion Scale. The scale is scored on a 5 point Likert scale (1 = Almost never; 5 = Almost always), and negative subscale items are reverse scored.

    Measure: Self-Compassion Scale Short Form (SCS-SF)

    Time: Baseline, Weeks 4, 8, 12

    Description: The Multidimensional Assessment of Interoceptive Awareness (MAIA-2) is a 37 item self-report scale designed to assess multiple aspects of interoception and interoceptive awareness. The scale assesses 8 aspects of interoceptive awareness: noticing, not-distracting, not-worrying, attention regulation, emotional awareness, self-regulation, body listening, and trusting. Subscales are summed and a higher total score represents a better outcome. Individual subscales will also be assessed, especially Body Listen, Body Trust, and Self-Regulation.

    Measure: Multidimensional Assessment of Interoceptive Awareness (MAIA-2)

    Time: Baseline, Weeks 4, 8, 12

    Description: The adult self-report COVID-19 Responses to Stress Questionnaire is a 72-item survey. Responses are recorded on a 4-point Likert scale (1 = Not at All, 4 = Very/A lot). Items in the RSQ cover 5 factors of coping and stress responses: primary control engagement coping (i.e., problem solving, emotional expression, emotional modulation), secondary control engagement coping (i.e., positive thinking, cognitive restructuring, acceptance, distraction), disengagement coping (i.e., avoidance, denial, wishful thinking); involuntary engagement (e.g., physiological arousal, rumination), and involuntary disengagement (e.g., emotional numbing).

    Measure: Responses to Stress Questionnaire - COVID -19 (RSQ-COVID-19) Stress coping style (disengagement, involuntary engagement)

    Time: Baseline, Weeks 12, 24

    Description: This is a 20-item self-report measure of decentering and is conceptualized as a protective factor and capable of measuring resilience to depressive relapse. The EQ uses a 5-point Likert scale with responses from "never" to "all the time". A sample item from the decentering subscale is "I can observe unpleasant feelings without being drawn into them."

    Measure: Experiences Questionnaire (EQ) (Rumination and Decentering)

    Time: Baseline, Weeks 4, 8, 12

    Description: Computer Adaptive Testing for Mental Health (CAT-MH) interviews are diagnostic interviews designed to be completed online using a computer, tablet or phone. Items from each of the modules for depression (CAT-DI), anxiety (ANX-CAT), mania and hypomania (M/HM-CAT), PTSD (PTSD-CAT), psychosis (PSY-S-CAT), suicidality (SS-CAT), and substance abuse (SUD-CAT) are chosen from large item banks based on multidimensional item response theory, adapting each item presented to the individual's severity so that different individuals are tested with different items depending on their severity level.

    Measure: Computerized Adaptive Testing for Mental Health (CAT-MH) Interviews

    Time: Screening, Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24

    Description: The Beck Depression Inventory (BDI-II) is a 21-item self-report scale designed to assess depression severity over the past 2 weeks with well-established internal consistency, reliability and validity.

    Measure: Beck Depression Inventory (BDI-II)

    Time: Baseline

    Description: Rank Desire for each intervention option will be assessed at baseline.

    Measure: Rank Desire

    Time: Baseline

    Description: Credibility/Expectancy for the assigned option will be assessed at Week 2. Treatment expectancy and credibility for each arm will be assessed with the 4-item Credibility/ Expectancy Questionnaire (CEQ)

    Measure: Credibility and Expectancy

    Time: Week 2

    Description: The COVID-19 Fear scale is a 7-item questionnaire recorded on a 5-point Likert scale (1 = Strongly Disagree to 5 = Strongly Agree). Responses to scale items were found to positively correlate with perceived vulnerability, hospital anxiety, and depression. Sample questions include "I am most afraid of coronavirus-19," and "It makes me uncomfortable to think about coronavirus-19."

    Measure: COVID-19 Fear

    Time: Baseline, Week 12

    Description: Participants will be asked to self-report on REDCap.

    Measure: COVID-19 status (self-report)

    Time: Week 0, 4, 8, 12, 16, 20, 24

    Description: Participants will be asked to complete a salivary sample to assess COVID-19 status. COVID-19 IgG samples: Antibodies for COVID-19 will be sampled at week 12 among all participants to establish whether they were exposed to COVID-19 during the study. They will place samples immediately in the freezer.

    Measure: COVID-19 status (salivary IgG)

    Time: Week 12

    Description: The UCI Oral Health Questionnaire is an 12-item survey that asks sociodemographic questions, questions about oral and physical health, as well as additional oral health questions drawn from the WHO Oral Health Survey. The questionnaire includes basic questions about dental health characteristics of participants to be used as an exclusion criteria for the salivary collection portion of the study and to track changes in oral health that might impact salivary data collection.

    Measure: UCI Oral Health Questionnaire

    Time: Screening and at Week 12

    Description: The Home Skills Use Diary will be completed for the 8 weeks during the intervention period and will come in two types (1: weekly mindfulness practice and resource use diary for the MBCT-R group and 2: General CBT coping skills use diary card for both the iCBT and CHA MindWell arms).

    Measure: Home Skills Use Diary

    Time: Weeks 1, 2, 3, 4, 5, 6, 7, 8

    Description: The Adverse Event Patient Participant Self-Report Form will be systematically assessed at assessment timepoints (baseline, 4-weeks, 8-weeks, 12-weeks, 16-weeks, 20-weeks and 24-weeks). In addition, group leaders and research coordinators will be trained to identify and report any adverse events that occur or are reported during weekly group visits.

    Measure: Adverse Event Patient Participant Self-Report Form

    Time: Baseline, Weeks 4, 8, 12, 16, 20, 24
    27 Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan

    To assess the depression in adults especially in post COVID-19 duration in the rural and urban settings.

    NCT04604080
    Conditions
    1. Depression, Anxiety
    Interventions
    1. Other: service of questionnaire
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: % prevalence of depression in adult population of south punjab will be assessed

    Measure: Prevalence estimation of depression in adults

    Time: study will be completed in 15 days maximum
    28 Harnessing Network Science to Personalize Scalable Interventions for Adolescent Depression: Do Idiographic Symptom Structures Predict Response to Single Session Interventions?

    We will recruit 216 subjects meeting the eligibility criteria. After completing a baseline battery session via secure video conferencing and 3-week phone survey period, adolescents will be randomly assigned to receive 1 of 3 web-based single session interventions (SSIs) at a second secure video conference session. This second session for the intervention will take place within 2-3 weeks after the phone survey period. Immediately pre- and post-SSI, adolescents will complete a limited number of self-report questionnaires to index shifts in proximal outcomes. Participants, both adult and youth, will complete additional follow-up questionnaires 3, 6, 12, 18, and 24 months post-intervention. Participants will complete the intervention, including the pre- and post- SSI questionnaires, and follow-up surveys on their own.

    NCT04607902
    Conditions
    1. Depression
    Interventions
    1. Behavioral: Supportive Therapy SSI
    2. Behavioral: Behavioral Activation SSI
    3. Behavioral: Growth Mindset SSI
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: The Children's Depression Inventory (CDI) 2 - short form (CDI-SF) is a reliable, valid measure of youth-reported depression severity, normed for youth age and sex and yielding raw and T scores.

    Measure: Change in adolescent depressive symptom severity

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Secondary Outcomes

    Description: The Children's Depression Inventory (CDI) 2 - parent form will be used to note differences in youth depression severity.

    Measure: Changes in parent-reported adolescent symptom severity

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Other Outcomes

    Description: Parents will report demographic, family, and other background information (e.g. age, sex, gender identity, race, mental health treatment history).

    Measure: Demographics

    Time: Pre-intervention only (sex, race); Pre-intervention, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up (age, gender identity, mental health treatment history)

    Description: Youth will complete the Pubertal Development Scale, given effects of puberty on depression onset.

    Measure: Pubertal development

    Time: Pre-intervention only

    Description: The ACEs questionnaire will ask parents about their child's and their own exposure to violence, childhood emotional, physical, or sexual abuse, and household dysfunction during childhood.

    Measure: Adverse Childhood Experiences (ACEs) for parent and child

    Time: Pre-intervention only

    Description: Adolescents' self-hate will be assessed using the 7-item Self-Hate Scale (SHS). Adolescents will indicate the extent to which each statement is true for them (e.g. "I hate myself") on a 7-point Likert scale. The SHS is a valid measure of self-hate, with excellent internal consistency.

    Measure: Self-Hate and related constructs

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Adolescents will complete the 99-item version of the IDAS-II. Respondents indicate the extent to which they had experienced each symptom "during the past two weeks, including today" on a 5-point scale ranging from not at all to extremely. The IDAS contains scales evaluating levels of Dysphoria; Well-Being; Panic; Suicidality, Lassitude, and Insomnia; Social Anxiety and Ill Temper; Traumatic Intrusions scale; and Appetite Loss and Appetite Gain; and Depression and Dysphoria. The IDAS-II is well-validated and nationally-normed for use with adolescents.

    Measure: Inventory of Depression and Anxiety Symptoms (IDAS-II)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Given high comorbidity between depression and anxiety, adolescent anxiety symptom severity will be assessed via adolescent and parent reports using the SCARED: a reliable, valid, widely used youth anxiety assessment with analog parent and youth-report forms.

    Measure: Screen for Child Anxiety and Related Disorders (SCARED)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Youths' approach versus disengagement from rewarding activities will be assessed via the BADS, a 9-item youth-report questionnaire with strong reliability, predictive validity, and sensitivity to change following BA for adolescent MD.

    Measure: Behavioral Activation for Depression Scale (BADS)-Short Form

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The SRET is a web-based behavioral measure of self-referent information processing biases that assesses judgements of self-descriptiveness, response latencies and free recall of emotionally valanced stimuli. Adolescents will make decisions about whether positive and negative adjectives are self-descriptive. Participants view various adjectives (26 positive adjectives, 26 negative adjectives) one at a time and make rapid judgments about whether or not each word presented described themselves following word offset. Participants will be told to use the Q or P keys on their keyboard to answer whether the word described them or not. Each trial will be followed by a 1,500 ms intertrial interval.

    Measure: Self-Referential Encoding Task (SRET)

    Time: Pre-intervention

    Description: The DRS-2 is a 9-item measure evaluating restrictive eating, bingeing, and purging behaviors in participants. 6 items ask adolescents whether or not they have engaged in restrictive eating, bingeing, or purging behaviors in the past year or in the past 3 months (0 = no; 1 = yes). The other 3 items assess the frequency of these behaviors over the past 28 days.

    Measure: The Dietary Restriction Screener (DRS)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Four items from a self-report version of the SITBI-SF will be used to assess each adolescent's lifetime history of suicide ideation, suicide attempts, and deliberate self-harm. The SITBI-SF is a widely used measure of the continuum of suicidality and self-harm and has demonstrated high test-retest reliability, high internal consistency, and moderate-to-high concurrent validity. Score range for this measure can range widely (per wide variation in instances of self-harming behaviors across one's lifetime); thus, we anticipate a minimum score of 0 and are unable to predict the top (maximum) score.

    Measure: Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The SCSC is a 20-item scale measuring youths' perceived ability to shape the personal impact of objective conditions on oneself, by adjusting oneself to fit those conditions. Youth rate agreement with items reflecting various kinds of secondary control, such as adjusting cognition ("When something bad happens, I can find a way to think about it that makes me feel better"). The SCSC has shown acceptable reliability and validity in a large youth sample.

    Measure: Secondary Control Scale for Children (SCSC)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The Becks Hopelessness Scale (BHS) asks both parents and youth to rate 4 statements based on their sense of hopelessness. Participants rate the 4 statements on a 4 point scale ranging from 0 (Absolutely Disagree) to 3 (Absolutely Agree). Total score ranges from 0 to 12, with higher scores indicating greater levels of hopelessness.

    Measure: Hopelessness

    Time: Immediately Pre- to Immediately Post-intervention; Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The Primary Control Scale for Children (PCSC) is a 24-item scale measuring youths' perceived ability to influence or alter objective events or conditions through personal effort. Youth rate agreement with statements about their ability to exert primary control (e.g., "I can do well on tests if I study hard"; "I can get other kids to like me if I try"). This PCSC has shown acceptable internal consistency, 6-month test-retest reliability, and strong inverse relations to adolescent depressive symptoms.

    Measure: Perceived agency

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The IPTQ asks youth to rate the extent of their agreement with three statements linked to the malleability of personality, using a 1-to-7 Likert scale (e.g. "Your personality is something about you that you can't change very much." Higher summed scores on these three items indicate a stronger fixed personality mindset, a lower scores, a stronger growth personality mindset.

    Measure: Implicit Personality Theory Questionnaire (IPTQ)

    Time: Immediately Pre- to Immediately Post-intervention; Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The BFAMG provides an overview of family functioning. Adolescents and parents rate 14 statements describing the family (e.g. "We feel loved in our family.") using a 0-3 Likert scale.

    Measure: Brief Family Assessment Measure (General Scale)

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The MVPS is a self-report scale assessing adolescents' experiences of peer victimization. This study will include the social manipulation, verbal victimization, and physical victimization scales, totaling 12 items. Adolescents rate how often peers have victimized them in various ways in the past year (e.g. "called me names"; "tried to turn my friends against me").

    Measure: Multidimensional Peer Victimization Scale

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The ULS is a widely used self-report scale of loneliness in adolescents. The brief 8-item version will be used here. Adolescents rate agreement with 8 items reflecting loneliness (e.g. "I feel left out"; "I feel isolated from others"). The ULS has shown adequate reliability and validity in adolescent samples.

    Measure: UCLA Loneliness Scale

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: The BSI-18 is a valid, reliable screening tool for adult (here, parental) psychological distress. Adult respondents rate endorsement of 18 physical and emotional complaints on a 0-4 Likert scale. The BSI-18 includes 3 subscales for somatic, anxiety, and depressive symptoms, respectively. The total sum score yields an additional total distress score.

    Measure: Brief Symptom Inventory-18

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Parents will complete the Barriers to Accessing Care Evaluation at baseline, modified for use by parents. Parents rate the degree to which various beliefs, concerns, circumstances, and logistical difficulties have stopped, delayed or discouraged them from getting professional care for their child's mental health problem. Higher total scores indicate greater perceived barriers to care.

    Measure: Perceived barriers to treatment

    Time: Pre-SSI only

    Description: Prognostic Pessimism for Depression (PPD) consists of five short questions, adapted from previous research, that aim to quantify a participants' perception of depression as a fixed or malleable condition. Both parents and adolescents will complete the PPD. Questions ask how permanent participants expect depression to be, why, and what might make it less so. An analogous set of questions are posed to parents, who are asked to respond about their children.

    Measure: Prognostic Pessimism For Depression

    Time: Pre-intervention to 3-month follow-up; Pre-intervention to 6-month follow-up; Pre-intervention to 12-month follow-up; Pre-intervention to 18-month follow-up; Pre-intervention to 24-month follow-up

    Description: Adapted from CDC Item Bank questions, these questions ask parents about the effects of COVID-19 on their families. Questions ask about stress caused by the pandemic, coping, illness, and effects on other items such as finances, mental health treatment, and employment.

    Measure: COVID-19 Items

    Time: Pre-intervention only

    Description: The ESM surveys will include selected items from the Patient Health Questionnaire-9, a widely-used measure of adolescent and adult depressive symptoms. Items will assess symptoms that could plausibly shift in any 2-3 hour period. At the end of the final survey on each day, adolescents will be asked two additional free response questions: "What was the most pleasant event today?" and "What was the most unpleasant event today?".

    Measure: Ecological Sampling Method Surveys (ESM)

    Time: Pre-intervention only
    29 Assisting Family Physicians With Gaps in Mental Health Care Generated by the COVID-19 Pandemic: A Randomized Controlled Trial

    During pandemics older adults with chronic physical conditions are a particularly vulnerable population for unmet mental health needs. This is a consequence of a number of factors which include decreased access to their doctors because of restrictions in visits in order to decrease risk of disease transmission and because doctors are seconded to provide medical services in areas of high priority. Since Public Health authorities worry that pandemics may be a reality of the future, this study is being operationalized during the present COVID-19 pandemic in order to see what can be learned about different ways to provide mental health care under such constraints. The study offers evidence-based approaches to managing feelings of anxiety or depression that may have existed prior to the onset of a pandemic, or that have arisen during a pandemic. It uses principles of cognitive behavioural therapy in which participants are offered self-care tools to help them develop strategies for dealing with their various symptoms. These tools have already been shown by the team to be effective in other contexts in studies DIRECT-sc (Effectiveness of a supported self-care intervention for depression compared to an unsupported intervention in older adults with chronic physical illnesses) and CanDIRECT (Effectiveness of a telephone-supported depression self-care intervention for cancer survivors). The present study, PanDIRECT (Assisting Family Physicians with Gaps in Mental Health Care Generated by the COVID-19 Pandemic), aims to answer the following questions: 1. Can these tools be used in the community care of mental health problems during pandemics? 2. Are they acceptable to patients? 3. Using a randomized control trial, does lay-coaching of use of these tools improve their use and patient outcomes? 4. Do family practitioners value patient information sent to them at the end of the trial

    NCT04609371
    Conditions
    1. Mental Health Wellness 1
    2. Coaching
    3. Pandemic
    4. Depression, Anxiety
    5. Self-care Tools
    Interventions
    1. Behavioral: self-care tools
    2. Behavioral: lay telephone coaching
    MeSH:Depression Depressive Disorder
    HPO:Depressivity

    Primary Outcomes

    Description: Number of consenting participants out of total number contacted over the recruitment period

    Measure: Consent rate

    Time: At recruitment

    Description: Investigators will report on rates of missing data from baseline and follow-up questionnaires

    Measure: Data completion rate

    Time: From recruitment launch to completion of follow-up (4 months)

    Description: Logs and checklists will be used to evaluate completion of intervention, as per protocol

    Measure: Fidelity of intervention completion

    Time: A 8 week follow-up

    Description: Using the validated 9 item Patient Health Questionnaire (PHQ-9). Scores range from 0 to 27 - higher score indicates more severe depression

    Measure: Severity of depression symptoms

    Time: At baseline

    Description: Using the validated 9 item Patient Health Questionnaire (PHQ-9). Scores range from 0 to 27 - higher score indicates more severe depression

    Measure: Severity of depression symptoms

    Time: At 8 week follow-up

    Description: Using the validated 7 item General Anxiety Disorder (GAD-7) instrument. Scores range from 0 to 21 - higher score indicates more severe anxiety

    Measure: Severity of anxiety symptoms

    Time: At baseline

    Description: Using the validated 7 item General Anxiety Disorder (GAD-7) instrument. Scores range from 0 to 21 - higher score indicates more severe anxiety

    Measure: Severity of anxiety symptoms

    Time: At 8 week follow-up

    Description: Using questions developed by the team and administrative databases to assess use of hospital and mental health care services

    Measure: Use of health care services

    Time: At baseline

    Description: Using questions developed by the team and administrative databases to assess use of hospital and mental health care services

    Measure: Use of health care services

    Time: At 8 week follow-up

    Description: Using adherence questions developed by the team, not scored

    Measure: Use of the self-care materials

    Time: At 8 week follow-up

    HPO Nodes


    HP:0000716: Depressivity
    Genes 460
    LMAN2L ZIC2 WFS1 TRNL1 PROKR2 COL7A1 NODAL DNAJC13 LINS1 LIMK1 PDE11A POLG FGFR1 COL7A1 WDR11 SIX3 CRADD GP1BB SNCA HTT MAPT SEC24C C19ORF12 ATXN2 CRBN WFS1 C9ORF72 PRKN DISP1 TARDBP GAS1 PER2 ADH1C LRRK2 FOXH1 CDH23 MECP2 ELN DNAJC6 GDAP2 OCRL GPR35 CHCHD10 JMJD1C MAN1B1 UFD1 ARMC5 POLG VCP COX2 DLL1 SIX3 GTF2I MLH3 FGF8 PDGFB C12ORF4 ATXN8 FAN1 PINK1 FLT4 MSH2 FOXH1 TCF4 HTR2A MSTO1 SLC2A1 TWNK CDON CSF1R VCP GAS1 SLC6A4 FIG4 MAN2B1 ARSA TRNH PROK2 PRPH MBOAT7 TET2 PRNP CACNA1H GLA NODAL COASY CLN6 SHH DISP1 DNAJC5 PDGFRB PON1 AIP GLI2 SLC20A2 FMR1 DISP1 HLA-DQB1 TWNK KDM5B IDUA SRPX2 FGF8 MSTO1 KISS1R TDGF1 AMACR TGFBR2 BCR ARSG TRNS2 GLI2 FGF8 TRNS1 PRKACA OPTN NOTCH3 HTT ATXN8OS XPR1 NR4A2 FGFR1 PSAP CACNA1G HARS1 DGUOK C9ORF72 ATXN10 ND4 ND5 TSC1 ATP1A3 GNAS CDON STAG2 TAF15 GNAS PRKAR1A SIX3 COX1 NSUN2 B3GALNT2 MST1 PIK3CA EZR USH1G NEFH ZIC2 BCS1L DCPS PAH TBK1 TWNK AARS2 KRAS ST3GAL3 FGF8 ABCA7 SHH ADGRV1 HMBS MYO7A RRM2B STAG2 DCTN1 KCTD17 HTT NODAL UNC13A PTCH1 ATXN2 ZIC2 USH1C CC2D1A SLC2A3 GAS1 PGAP1 TRAPPC9 FMO3 CEP85L KCNJ2 PPT1 TRNF TECR C9ORF72 CCNF PLA2G6 WHRN CDON NHLRC1 XK UCHL1 CLRN1 ANXA11 DAO SOD1 CDKN1A POLG FGF14 PTCH1 FRRS1L GLI2 CASR ATP1A3 EPHA4 USH2A MYO7A SNCAIP COQ2 GABRB3 TAC3 GABRA1 PARK7 DCTN1 SLC25A4 CRKL HS6ST1 THOC2 HLA-DQB1 SMC1A PRNP MLH1 CIB2 GNAS GRIK2 PRNP TOR1A GIGYF2 AIMP1 GRN NEK1 C9ORF72 ANOS1 CYP27A1 CBS PDGFRB CDKN1B MEN1 PINK1 PPP2R2B TBC1D7 AP2S1 HMBS HNRNPA1 USP8 TBK1 FA2H PRNP GLUD2 TRNS2 RREB1 MED25 BMPR1A CEP78 ARVCF NDST1 PTS PANK2 GCH1 PMS1 PON3 PIGC CLIP2 TBX1 DNMT1 TACR3 FUS EHMT1 POLG SYNJ1 RPS6KA3 MAPT MAN2B1 FBXO31 BAZ1B SNCA RSRC1 PRSS12 GBA FGF17 PDGFRB PDCD1 FUS TTC19 TRNQ RRM2B RFC2 DCTN1 SIX3 TUSC3 TDGF1 PRKCG TBP CDKN2C PODXL ATRX KISS1 PFN1 VCP GNRHR CISD2 PDGFB CDON ASXL1 CLCN4 MED23 EPM2A GNAS JPH3 JRK SGCE HNMT TK2 TRNL2 ZIC2 CDH23 GNAS LRRK2 GLE1 EPCAM VCP TMEM106B COX3 SMPD1 GABRG2 FOXH1 PRNP VPS13C SNCA ND1 VPS35 PON2 PPARGC1A EIF4G1 FGF8 WASHC4 POLG2 PRNP DNA2 FMN2 TGIF1 DNMT1 SLC18A2 SPRY4 TOR1A CHMP2B ARMC5 PTCH1 TDGF1 TSC2 SHH CARS1 THOC2 TWNK GLI2 CLCN4 RPS20 GBA HLA-DRB1 SRSF2 ATXN10 GAS1 RUNX1 GNA11 ESPN COMT AFG3L2 PANK2 TBX1 TGIF1 CHCHD10 KCTD17 TARDBP GTF2IRD1 NSMF IQSEC1 PAH GABRG2 PTCH1 CBL MATR3 SLC45A1 GNRH1 FOXH1 TRNS1 CFAP410 PLA2G6 SQSTM1 TGIF1 SPAST SEMA4A C9ORF72 VPS13A SQSTM1 CLIP1 CTSF POLG MAPT TDGF1 FGF14 TRNN TNIK TRNW DLL1 CHMP2B METTL23 TRNL1 TET3 SHH TGIF1 TBP PER3 MSH6 ND6 GRIN2A FGFR1 GLT8D1 PDZD7 ATXN8OS VAPB STX16 POLG MMP1 CACNA1G FMR1 ATP7B SARS1 EDC3 LMNB1 CPOX ERBB4 UBQLN2 MAPK1 DRD2 TREM2 TREM2 NODAL SGCE TBL2 DLL1 COQ2 CDKN2B ATP13A2 HIRA ZC3H14 CHD7 PSEN1 GSN ANG DMPK PCDH15 GPR101 PMS2 DLL1 DUSP6 KCNT1 HTRA2 GBA DISP1 PTPN22
    Protein Mutations 4
    A1298C C677T V158M V66M

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000716: Depressivity
    Genes 460
    LMAN2L ZIC2 WFS1 TRNL1 PROKR2 COL7A1 NODAL DNAJC13 LINS1 LIMK1 PDE11A POLG FGFR1 COL7A1 WDR11 SIX3 CRADD GP1BB SNCA HTT MAPT SEC24C C19ORF12 ATXN2 CRBN WFS1 C9ORF72 PRKN DISP1 TARDBP GAS1 PER2 ADH1C LRRK2 FOXH1 CDH23 MECP2 ELN DNAJC6 GDAP2 OCRL GPR35 CHCHD10 JMJD1C MAN1B1 UFD1 ARMC5 POLG VCP COX2 DLL1 SIX3 GTF2I MLH3 FGF8 PDGFB C12ORF4 ATXN8 FAN1 PINK1 FLT4 MSH2 FOXH1 TCF4 HTR2A MSTO1 SLC2A1 TWNK CDON CSF1R VCP GAS1 SLC6A4 FIG4 MAN2B1 ARSA TRNH PROK2 PRPH MBOAT7 TET2 PRNP CACNA1H GLA NODAL COASY CLN6 SHH DISP1 DNAJC5 PDGFRB PON1 AIP GLI2 SLC20A2 FMR1 DISP1 HLA-DQB1 TWNK KDM5B IDUA SRPX2 FGF8 MSTO1 KISS1R TDGF1 AMACR TGFBR2 BCR ARSG TRNS2 GLI2 FGF8 TRNS1 PRKACA OPTN NOTCH3 HTT ATXN8OS XPR1 NR4A2 FGFR1 PSAP CACNA1G HARS1 DGUOK C9ORF72 ATXN10 ND4 ND5 TSC1 ATP1A3 GNAS CDON STAG2 TAF15 GNAS PRKAR1A SIX3 COX1 NSUN2 B3GALNT2 MST1 PIK3CA EZR USH1G NEFH ZIC2 BCS1L DCPS PAH TBK1 TWNK AARS2 KRAS ST3GAL3 FGF8 ABCA7 SHH ADGRV1 HMBS MYO7A RRM2B STAG2 DCTN1 KCTD17 HTT NODAL UNC13A PTCH1 ATXN2 ZIC2 USH1C CC2D1A SLC2A3 GAS1 PGAP1 TRAPPC9 FMO3 CEP85L KCNJ2 PPT1 TRNF TECR C9ORF72 CCNF PLA2G6 WHRN CDON NHLRC1 XK UCHL1 CLRN1 ANXA11 DAO SOD1 CDKN1A POLG FGF14 PTCH1 FRRS1L GLI2 CASR ATP1A3 EPHA4 USH2A MYO7A SNCAIP COQ2 GABRB3 TAC3 GABRA1 PARK7 DCTN1 SLC25A4 CRKL HS6ST1 THOC2 HLA-DQB1 SMC1A PRNP MLH1 CIB2 GNAS GRIK2 PRNP TOR1A GIGYF2 AIMP1 GRN NEK1 C9ORF72 ANOS1 CYP27A1 CBS PDGFRB CDKN1B MEN1 PINK1 PPP2R2B TBC1D7 AP2S1 HMBS HNRNPA1 USP8 TBK1 FA2H PRNP GLUD2 TRNS2 RREB1 MED25 BMPR1A CEP78 ARVCF NDST1 PTS PANK2 GCH1 PMS1 PON3 PIGC CLIP2 TBX1 DNMT1 TACR3 FUS EHMT1 POLG SYNJ1 RPS6KA3 MAPT MAN2B1 FBXO31 BAZ1B SNCA RSRC1 PRSS12 GBA FGF17 PDGFRB PDCD1 FUS TTC19 TRNQ RRM2B RFC2 DCTN1 SIX3 TUSC3 TDGF1 PRKCG TBP CDKN2C PODXL ATRX KISS1 PFN1 VCP GNRHR CISD2 PDGFB CDON ASXL1 CLCN4 MED23 EPM2A GNAS JPH3 JRK SGCE HNMT TK2 TRNL2 ZIC2 CDH23 GNAS LRRK2 GLE1 EPCAM VCP TMEM106B COX3 SMPD1 GABRG2 FOXH1 PRNP VPS13C SNCA ND1 VPS35 PON2 PPARGC1A EIF4G1 FGF8 WASHC4 POLG2 PRNP DNA2 FMN2 TGIF1 DNMT1 SLC18A2 SPRY4 TOR1A CHMP2B ARMC5 PTCH1 TDGF1 TSC2 SHH CARS1 THOC2 TWNK GLI2 CLCN4 RPS20 GBA HLA-DRB1 SRSF2 ATXN10 GAS1 RUNX1 GNA11 ESPN COMT AFG3L2 PANK2 TBX1 TGIF1 CHCHD10 KCTD17 TARDBP GTF2IRD1 NSMF IQSEC1 PAH GABRG2 PTCH1 CBL MATR3 SLC45A1 GNRH1 FOXH1 TRNS1 CFAP410 PLA2G6 SQSTM1 TGIF1 SPAST SEMA4A C9ORF72 VPS13A SQSTM1 CLIP1 CTSF POLG MAPT TDGF1 FGF14 TRNN TNIK TRNW DLL1 CHMP2B METTL23 TRNL1 TET3 SHH TGIF1 TBP PER3 MSH6 ND6 GRIN2A FGFR1 GLT8D1 PDZD7 ATXN8OS VAPB STX16 POLG MMP1 CACNA1G FMR1 ATP7B SARS1 EDC3 LMNB1 CPOX ERBB4 UBQLN2 MAPK1 DRD2 TREM2 TREM2 NODAL SGCE TBL2 DLL1 COQ2 CDKN2B ATP13A2 HIRA ZC3H14 CHD7 PSEN1 GSN ANG DMPK PCDH15 GPR101 PMS2 DLL1 DUSP6 KCNT1 HTRA2 GBA DISP1 PTPN22
    Protein Mutations 4
    A1298C C677T V158M V66M

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook